{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:36:33Z","timestamp":1794555393594,"version":"4.9.1"},"reference-count":469,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02673-w","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T23:02:56Z","timestamp":1782687776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biologics for cardiovascular diseases: from bench to bedside"],"prefix":"10.1038","volume":"11","author":[{"given":"Xiaochi","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruikun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8866-4041","authenticated-orcid":false,"given":"Fulei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanlian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nongyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3742-630X","authenticated-orcid":false,"given":"Jiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijun","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"2673_CR1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1146\/annurev-pharmtox-061724-080811","volume":"65","author":"P McGonigle","year":"2025","unstructured":"McGonigle, P. How biologics have changed the drug discovery landscape. Annu. Rev. Pharmacol. Toxicol. 65, 1054\u20131064 (2025).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2673_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41587-022-01630-6","volume":"41","author":"M Senior","year":"2023","unstructured":"Senior, M. Fresh from the biotech pipeline: fewer approvals, but biologics gain share. Nat. Biotechnol. 41, 174\u2013182 (2023).","journal-title":"Nat. Biotechnol."},{"key":"2673_CR3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/d41573-024-00041-3","volume":"23","author":"P Verdin","year":"2024","unstructured":"Verdin, P. Top companies and drugs by sales in 2023. Nat. Rev. Drug Discov. 23, 240 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2673_CR4","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","volume":"82","author":"GA Mensah","year":"2023","unstructured":"Mensah, G. A., Fuster, V., Murray, C. J. L. & Roth, G. A. Global burden of cardiovascular diseases and risks, 1990-2022. J. Am. Coll. Cardiol. 82, 2350\u20132473 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR5","first-page":"101138","volume":"49","author":"RSJ Goh","year":"2024","unstructured":"Goh, R. S. J. et al. The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East Asia, South Asia, South-East Asia, Central Asia, and high-income Asia Pacific regions. Lancet Reg. Health West Pac. 49, 101138 (2024).","journal-title":"Lancet Reg. Health West Pac."},{"key":"2673_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.tips.2022.06.001","volume":"43","author":"G Ciucci","year":"2022","unstructured":"Ciucci, G. et al. Biologics and cardiac disease: challenges and opportunities. Trends Pharmacol. Sci. 43, 894\u2013905 (2022).","journal-title":"Trends Pharmacol. Sci."},{"key":"2673_CR7","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"2673_CR8","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh, T. A. et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 44, 3627\u20133639 (2023).","journal-title":"Eur. Heart J."},{"key":"2673_CR9","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","volume":"83","author":"MJ Koren","year":"2024","unstructured":"Koren, M. J. et al. An \u201cInclisiran First\u201d strategy vs usual care in patients with atherosclerotic cardiovascular disease. J. Am. Coll. Cardiol. 83, 1939\u20131952 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR10","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1093\/eurheartj\/ehae519","volume":"45","author":"X Wu","year":"2024","unstructured":"Wu, X. et al. Clinical trials in-a-dish for cardiovascular medicine. Eur. Heart J. 45, 4275\u20134290 (2024).","journal-title":"Eur. Heart J."},{"key":"2673_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","volume":"24","author":"S Paul","year":"2024","unstructured":"Paul, S. et al. Cancer therapy with antibodies. Nat. Rev. Cancer 24, 399\u2013426 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2673_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40265-023-01855-y","volume":"83","author":"L Deng","year":"2023","unstructured":"Deng, L. & Xu, G. Update on the application of monoclonal antibody therapy in primary membranous nephropathy. Drugs 83, 507\u2013530 (2023).","journal-title":"Drugs"},{"key":"2673_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cpt.3308","volume":"116","author":"K Lim","year":"2024","unstructured":"Lim, K. et al. Clinical pharmacology strategies for bispecific antibody development: learnings from FDA-approved bispecific antibodies in oncology. Clin. Pharmacol. Ther. 116, 315\u2013327 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2673_CR14","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/JCO.23.00512","volume":"41","author":"SA Holstein","year":"2023","unstructured":"Holstein, S. A., Grant, S. J. & Wildes, T. M. Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future. J. Clin. Oncol. 41, 4416\u20134429 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2673_CR15","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1182\/blood.2023021944","volume":"144","author":"K Lee","year":"2024","unstructured":"Lee, K. et al. Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab. Blood 144, 1230\u20131235 (2024).","journal-title":"Blood"},{"key":"2673_CR16","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.tips.2024.10.005","volume":"45","author":"V Blay","year":"2024","unstructured":"Blay, V. & Pandiella, A. Strategies to boost antibody selectivity in oncology. Trends Pharmacol. Sci. 45, 1135\u20131149 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"2673_CR17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/s41586-024-08489-4","volume":"638","author":"D Bousbaine","year":"2025","unstructured":"Bousbaine, D. et al. Discovery and engineering of the antibody response to a prominent skin commensal. Nature 638, 1054\u20131064 (2025).","journal-title":"Nature"},{"key":"2673_CR18","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","volume":"44","author":"F Raal","year":"2023","unstructured":"Raal, F. et al. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Eur. Heart J. 44, 4272\u20134280 (2023).","journal-title":"Eur. Heart J."},{"key":"2673_CR19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S1473-3099(24)00565-6","volume":"25","author":"Y Okada","year":"2025","unstructured":"Okada, Y. et al. Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4\/5variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4\/5 mRNA vaccine: a randomised phase 3 trial. Lancet Infect. Dis. 25, 290\u2013300 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"2673_CR20","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2209367","volume":"387","author":"EJ Anderson","year":"2022","unstructured":"Anderson, E. J. et al. Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age. N. Engl. J. Med. 387, 1673\u20131687 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR21","doi-asserted-by":"publisher","first-page":"13301","DOI":"10.1021\/acs.chemrev.4c00472","volume":"124","author":"S Mikutis","year":"2024","unstructured":"Mikutis, S. & Bernardes, G. J. L. Technologies for targeted RNA degradation and induced RNA decay. Chem. Rev. 124, 13301\u201313330 (2024).","journal-title":"Chem. Rev."},{"key":"2673_CR22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41569-023-00860-8","volume":"20","author":"J Brandts","year":"2023","unstructured":"Brandts, J. & Ray, K. K. Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Nat. Rev. Cardiol. 20, 600\u2013616 (2023).","journal-title":"Nat. Rev. Cardiol."},{"key":"2673_CR23","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn, J. D. et al. A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 22, 2227\u20132235 (2018).","journal-title":"Cell Rep."},{"key":"2673_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","volume":"22","author":"C Diorio","year":"2025","unstructured":"Diorio, C., Teachey, D. T. & Grupp, S. A. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks. Nat. Rev. Clin. Oncol. 22, 10\u201327 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2673_CR25","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","volume":"29","author":"JH Park","year":"2023","unstructured":"Park, J. H. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat. Med. 29, 1710\u20131717 (2023).","journal-title":"Nat. Med."},{"key":"2673_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin, J. R. et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N. Engl. J. Med. 389, 148\u2013157 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR27","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","volume":"29","author":"R Houot","year":"2023","unstructured":"Houot, R. et al. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat. Med. 29, 2593\u20132601 (2023).","journal-title":"Nat. Med."},{"key":"2673_CR28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker, D. J. et al. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707\u2013715 (2023).","journal-title":"Nature"},{"key":"2673_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"2673_CR30","first-page":"88","volume":"40","author":"X Du","year":"2024","unstructured":"Du, X. et al. Progress of organoid platform in cardiovascular research. Bioact. Mater. 40, 88\u2013103 (2024).","journal-title":"Bioact. Mater."},{"key":"2673_CR31","doi-asserted-by":"publisher","first-page":"13020","DOI":"10.1021\/acs.chemrev.4c00423","volume":"124","author":"CS Swenson","year":"2024","unstructured":"Swenson, C. S., Mandava, G., Thomas, D. M. & Moellering, R. E. Tackling undruggable targets with designer peptidomimetics and synthetic biologics. Chem. Rev. 124, 13020\u201313093 (2024).","journal-title":"Chem. Rev."},{"key":"2673_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38039-x","volume":"14","author":"SB Ebrahimi","year":"2023","unstructured":"Ebrahimi, S. B. & Samanta, D. Engineering protein-based therapeutics through structural and chemical design. Nat. Commun. 14, 2411 (2023).","journal-title":"Nat. Commun."},{"key":"2673_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.chembiol.2023.09.015","volume":"31","author":"MJ Unti","year":"2024","unstructured":"Unti, M. J. & Jaffrey, S. R. Highly efficient cellular expression of circular mRNA enables prolonged protein expression. Cell Chem. Biol. 31, 163\u2013176.e165 (2024).","journal-title":"Cell Chem. Biol."},{"key":"2673_CR34","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","volume":"23","author":"N Pardi","year":"2024","unstructured":"Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases - advances, challenges and opportunities. Nat. Rev. Drug Discov. 23, 838\u2013861 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2673_CR35","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0140-6736(24)02151-2","volume":"404","author":"MD Russell","year":"2024","unstructured":"Russell, M. D. & Galloway, J. B. Driving down the cost of biologics: lessons from a nationalised health-care system. Lancet 404, 1723\u20131724 (2024).","journal-title":"Lancet"},{"key":"2673_CR36","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.stem.2024.01.007","volume":"31","author":"K Raniga","year":"2024","unstructured":"Raniga, K. et al. Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 31, 292\u2013311 (2024).","journal-title":"Cell Stem Cell"},{"key":"2673_CR37","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1007\/s00018-017-2546-5","volume":"74","author":"E Giacomelli","year":"2017","unstructured":"Giacomelli, E., Mummery, C. L. & Bellin, M. Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes. Cell Mol. Life Sci. 74, 3711\u20133739 (2017).","journal-title":"Cell Mol. Life Sci."},{"key":"2673_CR38","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCULATIONAHA.123.065880","volume":"149","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Metabolic reprogramming: a byproduct or a driver of cardiomyocyte proliferation? Circulation 149, 1598\u20131610 (2024).","journal-title":"Circulation"},{"key":"2673_CR39","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s44161-023-00377-w","volume":"2","author":"Y Xie","year":"2023","unstructured":"Xie, Y., Van Handel, B., Qian, L. & Ardehali, R. Recent advances and future prospects in direct cardiac reprogramming. Nat. Cardiovasc. Res. 2, 1148\u20131158 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"2673_CR40","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1161\/CIRCULATIONAHA.117.029343","volume":"136","author":"T Eschenhagen","year":"2017","unstructured":"Eschenhagen, T. et al. Cardiomyocyte regeneration: a consensus statement. Circulation 136, 680\u2013686 (2017).","journal-title":"Circulation"},{"key":"2673_CR41","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.stem.2010.12.008","volume":"8","author":"SJ Kattman","year":"2011","unstructured":"Kattman, S. J. et al. Stage-specific optimization of activin\/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 8, 228\u2013240 (2011).","journal-title":"Cell Stem Cell"},{"key":"2673_CR42","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/nprot.2017.033","volume":"12","author":"K Breckwoldt","year":"2017","unstructured":"Breckwoldt, K. et al. Differentiation of cardiomyocytes and generation of human engineered heart tissue. Nat. Protoc. 12, 1177\u20131197 (2017).","journal-title":"Nat. Protoc."},{"key":"2673_CR43","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1161\/CIRCULATIONAHA.123.067097","volume":"149","author":"T Liu","year":"2024","unstructured":"Liu, T. et al. Advanced cardiac patches for the treatment of myocardial infarction. Circulation 149, 2002\u20132020 (2024).","journal-title":"Circulation"},{"key":"2673_CR44","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.yjmcc.2021.10.005","volume":"163","author":"T Eschenhagen","year":"2022","unstructured":"Eschenhagen, T., Ridders, K. & Weinberger, F. How to repair a broken heart with pluripotent stem cell-derived cardiomyocytes. J. Mol. Cell. Cardiol. 163, 106\u2013117 (2022).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"2673_CR45","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nature19815","volume":"538","author":"Y Shiba","year":"2016","unstructured":"Shiba, Y. et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature 538, 388\u2013391 (2016).","journal-title":"Nature"},{"key":"2673_CR46","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nbt.4162","volume":"36","author":"YW Liu","year":"2018","unstructured":"Liu, Y. W. et al. Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates. Nat. Biotechnol. 36, 597\u2013605 (2018).","journal-title":"Nat. Biotechnol."},{"key":"2673_CR47","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nature13233","volume":"510","author":"JJ Chong","year":"2014","unstructured":"Chong, J. J. et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510, 273\u2013277 (2014).","journal-title":"Nature"},{"key":"2673_CR48","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-024-08463-0","volume":"639","author":"AF Jebran","year":"2025","unstructured":"Jebran, A. F. et al. Engineered heart muscle allografts for heart repair in primates and humans. Nature 639, 503\u2013511 (2025).","journal-title":"Nature"},{"key":"2673_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056264","volume":"12","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I\/IIa dose-escalation clinical trial. BMJ Open 12, e056264 (2022).","journal-title":"BMJ Open"},{"key":"2673_CR50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1152\/physrev.00052.2021","volume":"103","author":"NR Harris","year":"2023","unstructured":"Harris, N. R. et al. The ebb and flow of cardiac lymphatics: a tidal wave of new discoveries. Physiol. Rev. 103, 391\u2013432 (2023).","journal-title":"Physiol. Rev."},{"key":"2673_CR51","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.cardiores.2005.04.011","volume":"67","author":"J Dow","year":"2005","unstructured":"Dow, J., Simkhovich, B. Z., Kedes, L. & Kloner, R. A. Washout of transplanted cells from the heart: a potential new hurdle for cell transplantation therapy. Cardiovasc. Res. 67, 301\u2013307 (2005).","journal-title":"Cardiovasc. Res."},{"key":"2673_CR52","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jacbts.2020.11.017","volume":"6","author":"S Kawaguchi","year":"2021","unstructured":"Kawaguchi, S. et al. Intramyocardial Transplantation of Human iPS Cell-Derived Cardiac Spheroids Improves Cardiac Function in Heart Failure Animals. JACC Basic Transl. Sci. 6, 239\u2013254 (2021).","journal-title":"JACC Basic Transl. Sci."},{"key":"2673_CR53","first-page":"205","volume":"26","author":"Y Ichihara","year":"2024","unstructured":"Ichihara, Y. et al. First-in-human study of left ventricular remuscularization with induced pluripotent stem cell derived cardiomyocyte spheroids for severe ischemic heart failure patients: preliminary LAPiS study result. Eur. J. Heart Fail. 26, 205\u2013205 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"2673_CR54","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1161\/CIRCULATIONAHA.120.047904","volume":"143","author":"E Querdel","year":"2021","unstructured":"Querdel, E. et al. Human engineered heart tissue patches remuscularize the injured heart in a dose-dependent manner. Circulation 143, 1991\u20132006 (2021).","journal-title":"Circulation"},{"key":"2673_CR55","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.119.044974","volume":"143","author":"D El-Nachef","year":"2021","unstructured":"El-Nachef, D. et al. Engrafted human induced pluripotent stem cell-derived cardiomyocytes undergo clonal expansion in vivo. Circulation 143, 1635\u20131638 (2021).","journal-title":"Circulation"},{"key":"2673_CR56","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1161\/CIRCRESAHA.117.311504","volume":"122","author":"W Zhu","year":"2018","unstructured":"Zhu, W. et al. CCND2 overexpression enhances the regenerative potency of human induced pluripotent stem cell-derived cardiomyocytes: remuscularization of injured ventricle. Circ. Res. 122, 88\u201396 (2018).","journal-title":"Circ. Res."},{"key":"2673_CR57","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1161\/CIRCULATIONAHA.120.049497","volume":"144","author":"M Zhao","year":"2021","unstructured":"Zhao, M. et al. Cyclin D2 overexpression enhances the efficacy of human induced pluripotent stem cell-derived cardiomyocytes for myocardial repair in a swine model of myocardial infarction. Circulation 144, 210\u2013228 (2021).","journal-title":"Circulation"},{"key":"2673_CR58","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.omtm.2020.04.011","volume":"17","author":"KA Gerbin","year":"2020","unstructured":"Gerbin, K. A. et al. Delta-1 functionalized hydrogel promotes hESC-cardiomyocyte graft proliferation and maintains heart function post-injury. Mol. Ther. Methods Clin. Dev. 17, 986\u2013998 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2673_CR59","doi-asserted-by":"publisher","first-page":"eaax2992","DOI":"10.1126\/scitranslmed.aax2992","volume":"12","author":"X Sun","year":"2020","unstructured":"Sun, X. et al. Transplanted microvessels improve pluripotent stem cell-derived cardiomyocyte engraftment and cardiac function after infarction in rats. Sci. Transl. Med. 12, eaax2992 (2020).","journal-title":"Sci. Transl. Med."},{"key":"2673_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120033","volume":"251","author":"F Munarin","year":"2020","unstructured":"Munarin, F. et al. Engineered human myocardium with local release of angiogenic proteins improves vascularization and cardiac function in injured rat hearts. Biomaterials 251, 120033 (2020).","journal-title":"Biomaterials"},{"key":"2673_CR61","doi-asserted-by":"publisher","first-page":"dev201103","DOI":"10.1242\/dev.201103","volume":"150","author":"D Ottaviani","year":"2023","unstructured":"Ottaviani, D. et al. Maturing differentiated human pluripotent stem cells in vitro: methods and challenges. Development. 150, dev201103 (2023).","journal-title":"Development."},{"key":"2673_CR62","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s44161-023-00419-3","volume":"3","author":"D Selvakumar","year":"2024","unstructured":"Selvakumar, D. et al. Cellular heterogeneity of pluripotent stem cell-derived cardiomyocyte grafts is mechanistically linked to treatable arrhythmias. Nat. Cardiovasc. Res. 3, 145\u2013165 (2024).","journal-title":"Nat. Cardiovasc. Res."},{"key":"2673_CR63","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s40778-022-00221-0","volume":"8","author":"TB Meissner","year":"2022","unstructured":"Meissner, T. B., Schulze, H. S. & Dale, S. M. Immune editing: overcoming immune barriers in stem cell transplantation. Curr. Stem Cell Rep. 8, 206\u2013218 (2022).","journal-title":"Curr. Stem Cell Rep."},{"key":"2673_CR64","doi-asserted-by":"publisher","first-page":"963689724129036","DOI":"10.1177\/09636897241290367","volume":"33","author":"J Scholz","year":"2024","unstructured":"Scholz, J. et al. Human stem cell-derived cardiomyocytes integrate into the heart of monkeys with right ventricular pressure overload. Cell Transpl. 33, 9636897241290367 (2024).","journal-title":"Cell Transpl."},{"key":"2673_CR65","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/35070587","volume":"410","author":"D Orlic","year":"2001","unstructured":"Orlic, D. et al. Bone marrow cells regenerate infarcted myocardium. Nature 410, 701\u2013705 (2001).","journal-title":"Nature"},{"key":"2673_CR66","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature13309","volume":"509","author":"JH van Berlo","year":"2014","unstructured":"van Berlo, J. H. et al. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509, 337\u2013341 (2014).","journal-title":"Nature"},{"key":"2673_CR67","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1126\/science.1077857","volume":"298","author":"KD Poss","year":"2002","unstructured":"Poss, K. D., Wilson, L. G. & Keating, M. T. Heart regeneration in zebrafish. Science 298, 2188\u20132190 (2002).","journal-title":"Science"},{"key":"2673_CR68","doi-asserted-by":"publisher","first-page":"11889","DOI":"10.1073\/pnas.1834204100","volume":"100","author":"A Raya","year":"2003","unstructured":"Raya, A. et al. Activation of Notch signaling pathway precedes heart regeneration in zebrafish. Proc. Natl. Acad. Sci. USA 100, 11889\u201311895 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2673_CR69","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1073\/pnas.1311705111","volume":"111","author":"L Zhao","year":"2014","unstructured":"Zhao, L. et al. Notch signaling regulates cardiomyocyte proliferation during zebrafish heart regeneration. Proc. Natl. Acad. Sci. USA 111, 1403\u20131408 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2673_CR70","doi-asserted-by":"publisher","first-page":"13839","DOI":"10.1073\/pnas.1313192110","volume":"110","author":"M Xin","year":"2013","unstructured":"Xin, M. et al. Hippo pathway effector Yap promotes cardiac regeneration. Proc. Natl. Acad. Sci. USA 110, 13839\u201313844 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2673_CR71","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nature24045","volume":"550","author":"JP Leach","year":"2017","unstructured":"Leach, J. P. et al. Hippo pathway deficiency reverses systolic heart failure after infarction. Nature 550, 260\u2013264 (2017).","journal-title":"Nature"},{"key":"2673_CR72","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/ncb3149","volume":"17","author":"G D\u2019Uva","year":"2015","unstructured":"D\u2019Uva, G. et al. ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat. Cell Biol. 17, 627\u2013638 (2015).","journal-title":"Nat. Cell Biol."},{"key":"2673_CR73","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.cell.2009.04.060","volume":"138","author":"K Bersell","year":"2009","unstructured":"Bersell, K., Arab, S., Haring, B. & K\u00fchn, B. Neuregulin1\/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138, 257\u2013270 (2009).","journal-title":"Cell"},{"key":"2673_CR74","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1161\/CIRCRESAHA.112.267286","volume":"111","author":"O Odiete","year":"2012","unstructured":"Odiete, O., Hill, M. F. & Sawyer, D. B. Neuregulin in cardiovascular development and disease. Circ. Res. 111, 1376\u20131385 (2012).","journal-title":"Circ. Res."},{"key":"2673_CR75","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006288","volume":"12","author":"GW De Keulenaer","year":"2019","unstructured":"De Keulenaer, G. W. et al. Mechanisms of the multitasking endothelial protein NRG-1 as a compensatory factor during chronic heart failure. Circ. Heart Fail. 12, e006288 (2019).","journal-title":"Circ. Heart Fail."},{"key":"2673_CR76","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40256-023-00585-6","volume":"23","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Safety, tolerability, and pharmacokinetics of recombinant human neuregulin-1 in healthy Chinese subjects. Am. J. Cardiovasc. Drugs 23, 419\u2013428 (2023).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"2673_CR77","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.jacc.2009.12.044","volume":"55","author":"R Gao","year":"2010","unstructured":"Gao, R. et al. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J. Am. Coll. Cardiol. 55, 1907\u20131914 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR78","doi-asserted-by":"publisher","first-page":"A668","DOI":"10.1016\/S0735-1097(18)31209-9","volume":"71","author":"R Gao","year":"2018","unstructured":"Gao, R. et al. A phase III, randomized, double-blind, multicenter, placebo-controlled study of the efficacy and safety of NEUCARDIN\u2122 in patients with chronic heart failure. J. Am. Coll. Cardiol. 71, A668 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR79","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1161\/CIRCRESAHA.117.312166","volume":"123","author":"AE Hopf","year":"2018","unstructured":"Hopf, A. E. et al. Diabetes-induced cardiomyocyte passive stiffening is caused by impaired insulin-dependent titin modification and can be modulated by neuregulin-1. Circ. Res. 123, 342\u2013355 (2018).","journal-title":"Circ. Res."},{"key":"2673_CR80","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvq238","volume":"88","author":"A Brero","year":"2010","unstructured":"Brero, A. et al. Neuregulin-1beta1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes. Cardiovasc. Res. 88, 443\u2013452 (2010).","journal-title":"Cardiovasc. Res."},{"key":"2673_CR81","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.drudis.2013.01.010","volume":"18","author":"P Mendes-Ferreira","year":"2013","unstructured":"Mendes-Ferreira, P., De Keulenaer, G. W., Leite-Moreira, A. F. & Br\u00e1s-Silva, C. Therapeutic potential of neuregulin-1 in cardiovascular disease. Drug Discov. Today 18, 836\u2013842 (2013).","journal-title":"Drug Discov. Today"},{"key":"2673_CR82","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.cardfail.2023.10.471","volume":"30","author":"WH Tang","year":"2024","unstructured":"Tang, W. H. et al. Final analysis of safety and exploratory echo data in a phase 1, first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate JK07 in subjects with heart failure with reduced ejection fraction. J. Card. Fail. 30, 314 (2024).","journal-title":"J. Card. Fail."},{"key":"2673_CR83","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.1016\/j.apsb.2023.08.021","volume":"13","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Hippo pathway-manipulating neutrophil-mimic hybrid nanoparticles for cardiac ischemic injury via modulation of local immunity and cardiac regeneration. Acta Pharm. Sin. B. 13, 4999\u20135015 (2023).","journal-title":"Acta Pharm. Sin. B."},{"key":"2673_CR84","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13619-021-00077-5","volume":"10","author":"Z Ouyang","year":"2021","unstructured":"Ouyang, Z. & Wei, K. miRNA in cardiac development and regeneration. Cell Regen. 10, 14 (2021).","journal-title":"Cell Regen."},{"key":"2673_CR85","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1161\/CIRCRESAHA.124.323058","volume":"135","author":"E Marb\u00e1n","year":"2024","unstructured":"Marb\u00e1n, E. Deconstructing regenerative medicine: from mechanistic studies of cell therapy to novel bioinspired RNA drugs. Circ. Res. 135, 877\u2013885 (2024).","journal-title":"Circ. Res."},{"key":"2673_CR86","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.molmed.2024.03.004","volume":"30","author":"A Chabronova","year":"2024","unstructured":"Chabronova, A. et al. SnoRNAs in cardiovascular development, function, and disease. Trends Mol. Med. 30, 562\u2013578 (2024).","journal-title":"Trends Mol. Med."},{"key":"2673_CR87","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41569-024-01001-5","volume":"21","author":"A Caporali","year":"2024","unstructured":"Caporali, A. et al. Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease. Nat. Rev. Cardiol. 21, 556\u2013573 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"2673_CR88","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1016\/j.celrep.2019.05.005","volume":"27","author":"C Torrini","year":"2019","unstructured":"Torrini, C. et al. Common regulatory pathways mediate activity of MicroRNAs inducing cardiomyocyte proliferation. Cell Rep. 27, 2759\u20132771.e2755 (2019).","journal-title":"Cell Rep."},{"key":"2673_CR89","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbrc.2019.05.174","volume":"516","author":"Y Tao","year":"2019","unstructured":"Tao, Y. et al. miR-199a-3p promotes cardiomyocyte proliferation by inhibiting Cd151 expression. Biochem. Biophys. Res. Commun. 516, 28\u201336 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2673_CR90","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41586-019-1191-6","volume":"569","author":"K Gabisonia","year":"2019","unstructured":"Gabisonia, K. et al. MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs. Nature 569, 418\u2013422 (2019).","journal-title":"Nature"},{"key":"2673_CR91","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature11739","volume":"492","author":"A Eulalio","year":"2012","unstructured":"Eulalio, A. et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature 492, 376\u2013381 (2012).","journal-title":"Nature"},{"key":"2673_CR92","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1073\/pnas.1214608110","volume":"110","author":"M Mollova","year":"2013","unstructured":"Mollova, M. et al. Cardiomyocyte proliferation contributes to heart growth in young humans. Proc. Natl. Acad. Sci. USA 110, 1446\u20131451 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2673_CR93","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.cell.2015.05.026","volume":"161","author":"O Bergmann","year":"2015","unstructured":"Bergmann, O. et al. Dynamics of cell generation and turnover in the human heart. Cell 161, 1566\u20131575 (2015).","journal-title":"Cell"},{"key":"2673_CR94","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.yjmcc.2023.07.007","volume":"182","author":"MH Soonpaa","year":"2023","unstructured":"Soonpaa, M. H., Reuter, S. P., Castelluccio, P. F. & Field, L. J. Musings on intrinsic cardiomyocyte cell cycle activity and myocardial regeneration. J. Mol. Cell. Cardiol. 182, 86\u201391 (2023).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"2673_CR95","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.tem.2019.05.006","volume":"30","author":"KM Broughton","year":"2019","unstructured":"Broughton, K. M. & Sussman, M. A. Adult cardiomyocyte cell cycle detour: off-ramp to quiescent destinations. Trends Endocrinol. Metab. 30, 557\u2013567 (2019).","journal-title":"Trends Endocrinol. Metab."},{"key":"2673_CR96","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.1147949","volume":"318","author":"GL Semenza","year":"2007","unstructured":"Semenza, G. L. Life with oxygen. Science 318, 62\u201364 (2007).","journal-title":"Science"},{"key":"2673_CR97","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41392-024-01918-w","volume":"9","author":"W Yao","year":"2024","unstructured":"Yao, W., Hu, X. & Wang, X. Crossing epigenetic frontiers: the intersection of novel histone modifications and diseases. Signal Transduct. Target. Ther. 9, 232 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2673_CR98","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41569-023-00914-x","volume":"21","author":"M Weinberger","year":"2024","unstructured":"Weinberger, M. & Riley, P. R. Animal models to study cardiac regeneration. Nat. Rev. Cardiol. 21, 89\u2013105 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"2673_CR99","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cell.2018.02.014","volume":"173","author":"TMA Mohamed","year":"2018","unstructured":"Mohamed, T. M. A. et al. Regulation of cell cycle to stimulate adult cardiomyocyte proliferation and cardiac regeneration. Cell 173, 104\u2013116.e112 (2018).","journal-title":"Cell"},{"key":"2673_CR100","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1161\/CIRCULATIONAHA.121.057641","volume":"145","author":"RRE Abouleisa","year":"2022","unstructured":"Abouleisa, R. R. E. et al. Transient cell cycle induction in cardiomyocytes to treat subacute ischemic heart failure. Circulation 145, 1339\u20131355 (2022).","journal-title":"Circulation"},{"key":"2673_CR101","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature12054","volume":"497","author":"AI Mahmoud","year":"2013","unstructured":"Mahmoud, A. I. et al. Meis1 regulates postnatal cardiomyocyte cell cycle arrest. Nature 497, 249\u2013253 (2013).","journal-title":"Nature"},{"key":"2673_CR102","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41586-020-2228-6","volume":"582","author":"NUN Nguyen","year":"2020","unstructured":"Nguyen, N. U. N. et al. A calcineurin-Hoxb13 axis regulates growth mode of mammalian cardiomyocytes. Nature 582, 271\u2013276 (2020).","journal-title":"Nature"},{"key":"2673_CR103","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1126\/science.abg5159","volume":"373","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Reversible reprogramming of cardiomyocytes to a fetal state drives heart regeneration in mice. Science 373, 1537\u20131540 (2021).","journal-title":"Science"},{"key":"2673_CR104","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/cells12081166","volume":"12","author":"S Perveen","year":"2023","unstructured":"Perveen, S. et al. Direct reprogramming of resident non-myocyte cells and its potential for in vivo cardiac regeneration. Cells 12, 1166 (2023).","journal-title":"Cells"},{"key":"2673_CR105","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41392-020-00413-2","volume":"6","author":"R Gong","year":"2021","unstructured":"Gong, R. et al. Regulation of cardiomyocyte fate plasticity: a key strategy for cardiac regeneration. Signal Transduct. Target. Ther. 6, 31 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2673_CR106","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcdb.2021.05.019","volume":"122","author":"GA Garry","year":"2022","unstructured":"Garry, G. A., Bassel-Duby, R. & Olson, E. N. Direct reprogramming as a route to cardiac repair. Semin. Cell Dev. Biol. 122, 3\u201313 (2022).","journal-title":"Semin. Cell Dev. Biol."},{"key":"2673_CR107","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2010.07.002","volume":"142","author":"M Ieda","year":"2010","unstructured":"Ieda, M. et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142, 375\u2013386 (2010).","journal-title":"Cell"},{"key":"2673_CR108","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nature11139","volume":"485","author":"K Song","year":"2012","unstructured":"Song, K. et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 485, 599\u2013604 (2012).","journal-title":"Nature"},{"key":"2673_CR109","doi-asserted-by":"publisher","first-page":"12667","DOI":"10.1073\/pnas.1304053110","volume":"110","author":"R Wada","year":"2013","unstructured":"Wada, R. et al. Induction of human cardiomyocyte-like cells from fibroblasts by defined factors. Proc. Natl. Acad. Sci. USA 110, 12667\u201312672 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2673_CR110","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1101\/gad.305482.117","volume":"31","author":"H Zhou","year":"2017","unstructured":"Zhou, H. et al. ZNF281 enhances cardiac reprogramming by modulating cardiac and inflammatory gene expression. Genes Dev. 31, 1770\u20131783 (2017).","journal-title":"Genes Dev."},{"key":"2673_CR111","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.stemcr.2017.01.025","volume":"8","author":"M Abad","year":"2017","unstructured":"Abad, M. et al. Notch inhibition enhances cardiac reprogramming by increasing MEF2C transcriptional activity. Stem Cell Rep. 8, 548\u2013560 (2017).","journal-title":"Stem Cell Rep."},{"key":"2673_CR112","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature24454","volume":"551","author":"Z Liu","year":"2017","unstructured":"Liu, Z. et al. Single-cell transcriptomics reconstructs fate conversion from fibroblast to cardiomyocyte. Nature 551, 100\u2013104 (2017).","journal-title":"Nature"},{"key":"2673_CR113","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.apsb.2019.09.003","volume":"10","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Lineage reprogramming of fibroblasts into induced cardiac progenitor cells by CRISPR\/Cas9-based transcriptional activators. Acta Pharm. Sin. B 10, 313\u2013326 (2020).","journal-title":"Acta Pharm. Sin. B"},{"key":"2673_CR114","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ymthe.2021.10.015","volume":"30","author":"L Jiang","year":"2022","unstructured":"Jiang, L. et al. CRISPR activation of endogenous genes reprograms fibroblasts into cardiovascular progenitor cells for myocardial infarction therapy. Mol. Ther. 30, 54\u201374 (2022).","journal-title":"Mol. Ther."},{"key":"2673_CR115","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.116.024692","volume":"135","author":"TM Mohamed","year":"2017","unstructured":"Mohamed, T. M. et al. Chemical enhancement of in vitro and in vivo direct cardiac reprogramming. Circulation 135, 978\u2013995 (2017).","journal-title":"Circulation"},{"key":"2673_CR116","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1161\/01.CIR.0000105723.91637.1C","volume":"108","author":"SL House","year":"2003","unstructured":"House, S. L. et al. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation 108, 3140\u20133148 (2003).","journal-title":"Circulation"},{"key":"2673_CR117","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.omtm.2018.04.003","volume":"9","author":"L Carlsson","year":"2018","unstructured":"Carlsson, L. et al. Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1 week post-myocardial infarction in swine. Mol. Ther. Methods Clin. Dev. 9, 330\u2013346 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2673_CR118","first-page":"H1791","volume":"270","author":"K Harada","year":"1996","unstructured":"Harada, K. et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am. J. Physiol. 270, H1791\u2013H1802 (1996).","journal-title":"Am. J. Physiol."},{"key":"2673_CR119","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/hc0802.104407","volume":"105","author":"M Simons","year":"2002","unstructured":"Simons, M. et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105, 788\u2013793 (2002).","journal-title":"Circulation"},{"key":"2673_CR120","doi-asserted-by":"publisher","first-page":"I157","DOI":"10.1161\/01.CIRCULATIONAHA.105.525782","volume":"112","author":"M Gy\u00f6ngy\u00f6si","year":"2005","unstructured":"Gy\u00f6ngy\u00f6si, M. et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 112, I157\u2013I165 (2005).","journal-title":"Circulation"},{"key":"2673_CR121","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ymthe.2022.11.017","volume":"31","author":"V Anttila","year":"2023","unstructured":"Anttila, V. et al. Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting. Mol. Ther. 31, 866\u2013874 (2023).","journal-title":"Mol. Ther."},{"key":"2673_CR122","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41573-021-00355-6","volume":"21","author":"A Coll\u00e9n","year":"2022","unstructured":"Coll\u00e9n, A. et al. VEGFA mRNA for regenerative treatment of heart failure. Nat. Rev. Drug Discov. 21, 79\u201380 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2673_CR123","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1210\/endrev\/bnac009","volume":"43","author":"C Salomon","year":"2022","unstructured":"Salomon, C. et al. Extracellular vesicles and their emerging roles as cellular messengers in endocrinology: an endocrine society scientific statement. Endocr. Rev. 43, 441\u2013468 (2022).","journal-title":"Endocr. Rev."},{"key":"2673_CR124","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/cvr\/cvy055","volume":"114","author":"L Barile","year":"2018","unstructured":"Barile, L. et al. Cardioprotection by cardiac progenitor cell-secreted exosomes: role of pregnancy-associated plasma protein-A. Cardiovasc. Res. 114, 992\u20131005 (2018).","journal-title":"Cardiovasc. Res."},{"key":"2673_CR125","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.7150\/thno.72289","volume":"12","author":"M Mongui\u00f3-Tortajada","year":"2022","unstructured":"Mongui\u00f3-Tortajada, M. et al. Acellular cardiac scaffolds enriched with MSC-derived extracellular vesicles limit ventricular remodelling and exert local and systemic immunomodulation in a myocardial infarction porcine model. Theranostics 12, 4656\u20134670 (2022).","journal-title":"Theranostics"},{"key":"2673_CR126","doi-asserted-by":"publisher","first-page":"eabb0202","DOI":"10.1126\/scitranslmed.abb0202","volume":"13","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. Small extracellular vesicles containing miR-486-5p promote angiogenesis after myocardial infarction in mice and nonhuman primates. Sci. Transl. Med. 13, eabb0202 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2673_CR127","first-page":"201","volume":"38","author":"R Gallet","year":"2017","unstructured":"Gallet, R. et al. Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur. Heart J. 38, 201\u2013211 (2017).","journal-title":"Eur. Heart J."},{"key":"2673_CR128","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/eurheartj\/ehad636","volume":"45","author":"MY Emmert","year":"2024","unstructured":"Emmert, M. Y. et al. Intracoronary delivery of extracellular vesicles from human cardiac progenitor cells reduces infarct size in porcine acute myocardial infarction. Eur. Heart J. 45, 728\u2013732 (2024).","journal-title":"Eur. Heart J."},{"key":"2673_CR129","doi-asserted-by":"publisher","first-page":"601990","DOI":"10.3389\/fcvm.2020.601990","volume":"7","author":"CJ Charles","year":"2020","unstructured":"Charles, C. J. et al. Systemic mesenchymal stem cell-derived exosomes reduce myocardial infarct size: characterization with MRI in a porcine model. Front. Cardiovasc. Med. 7, 601990 (2020).","journal-title":"Front. Cardiovasc. Med."},{"key":"2673_CR130","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/eurheartj\/ehae089","volume":"45","author":"L Barile","year":"2024","unstructured":"Barile, L. & Marb\u00e1n, E. Injury minimization after myocardial infarction: focus on extracellular vesicles. Eur. Heart J. 45, 1602\u20131609 (2024).","journal-title":"Eur. Heart J."},{"key":"2673_CR131","doi-asserted-by":"publisher","first-page":"24622","DOI":"10.1021\/acsnano.3c07878","volume":"18","author":"X Cui","year":"2024","unstructured":"Cui, X. et al. Bioderived nanoparticles for cardiac repair. ACS Nano 18, 24622\u201324649 (2024).","journal-title":"ACS Nano"},{"key":"2673_CR132","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41592-022-01591-3","volume":"19","author":"S Cho","year":"2022","unstructured":"Cho, S. et al. Challenges and opportunities for the next generation of cardiovascular tissue engineering. Nat. Methods 19, 1064\u20131071 (2022).","journal-title":"Nat. Methods"},{"key":"2673_CR133","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202404264","volume":"36","author":"C Yu","year":"2024","unstructured":"Yu, C. et al. Chemically programmed hydrogels for spatiotemporal modulation of the cardiac pathological microenvironment. Adv. Mater. 36, e2404264 (2024).","journal-title":"Adv. Mater."},{"key":"2673_CR134","doi-asserted-by":"publisher","first-page":"48880","DOI":"10.1021\/acsami.4c09623","volume":"16","author":"Y Cao","year":"2024","unstructured":"Cao, Y., Fan, R., Zhu, K. & Gao, Y. Advances in functionalized hydrogels in the treatment of myocardial infarction and drug-delivery strategies. ACS Appl. Mater. Interfaces 16, 48880\u201348894 (2024).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2673_CR135","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/ejhf.449","volume":"18","author":"DL Mann","year":"2016","unstructured":"Mann, D. L. et al. One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure. Eur. J. Heart Fail. 18, 314\u2013325 (2016).","journal-title":"Eur. J. Heart Fail."},{"key":"2673_CR136","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jacc.2016.05.053","volume":"68","author":"SV Rao","year":"2016","unstructured":"Rao, S. V. et al. Bioabsorbable intracoronary matrix for prevention of ventricular remodeling after myocardial infarction. J. Am. Coll. Cardiol. 68, 715\u2013723 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR137","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8364382","volume":"2016","author":"KM French","year":"2016","unstructured":"French, K. M. et al. Fibronectin and cyclic strain improve cardiac progenitor cell regenerative potential in vitro. Stem Cells Int. 2016, 8364382 (2016).","journal-title":"Stem Cells Int."},{"key":"2673_CR138","first-page":"215","volume":"11","author":"G Buchkremer","year":"1989","unstructured":"Buchkremer, G. & Minneker, E. Efficiency of multimodal smoking cessation therapy combining transdermal nicotine substitution with behavioral therapy. Methods Find. Exp. Clin. Pharmacol. 11, 215\u2013218 (1989).","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"2673_CR139","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201800672","volume":"7","author":"D Bejleri","year":"2018","unstructured":"Bejleri, D. et al. A bioprinted cardiac patch composed of cardiac-specific extracellular matrix and progenitor cells for heart repair. Adv. Health. Mater. 7, e1800672 (2018).","journal-title":"Adv. Health. Mater."},{"key":"2673_CR140","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jacbts.2019.07.012","volume":"4","author":"JH Traverse","year":"2019","unstructured":"Traverse, J. H. et al. First-in-man study of a cardiac extracellular matrix hydrogel in early and late myocardial infarction patients. JACC Basic Transl. Sci. 4, 659\u2013669 (2019).","journal-title":"JACC Basic Transl. Sci."},{"key":"2673_CR141","doi-asserted-by":"publisher","first-page":"10216","DOI":"10.1021\/acsnano.4c00509","volume":"18","author":"F Zhang","year":"2024","unstructured":"Zhang, F. et al. Injectable and conductive nanomicelle hydrogel with \u03b1-tocopherol encapsulation for enhanced myocardial infarction repair. ACS Nano 18, 10216\u201310229 (2024).","journal-title":"ACS Nano"},{"key":"2673_CR142","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202403642","volume":"36","author":"K Roshanbinfar","year":"2024","unstructured":"Roshanbinfar, K. et al. Electrically conductive collagen-PEDOT:PSS hydrogel prevents post-infarct cardiac arrhythmia and supports hiPSC-cardiomyocyte function. Adv. Mater. 36, e2403642 (2024).","journal-title":"Adv. Mater."},{"key":"2673_CR143","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401368","volume":"11","author":"Z Zhao","year":"2024","unstructured":"Zhao, Z. et al. Tissue-penetrating ultrasound-triggered hydrogel for promoting microvascular network reconstruction. Adv. Sci. 11, e2401368 (2024).","journal-title":"Adv. Sci."},{"key":"2673_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401301","volume":"11","author":"XW Wang","year":"2024","unstructured":"Wang, X. W. et al. UV-triggered hydrogel coating of the double network polyelectrolytes for enhanced endothelialization. Adv. Sci. 11, e2401301 (2024).","journal-title":"Adv. Sci."},{"key":"2673_CR145","doi-asserted-by":"publisher","first-page":"e2400121","DOI":"10.1002\/smtd.202400121","volume":"8","author":"W Liu","year":"2024","unstructured":"Liu, W. et al. A whole-course-repair system based on stimulus-responsive multifunctional hydrogels for myocardial tissue regeneration. Small Methods 8, e2400121 (2024).","journal-title":"Small Methods"},{"key":"2673_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2024.09.056","volume":"189","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. A critical review on advances and challenges of bioprinted cardiac patches. Acta Biomater. 189, 1\u201324 (2024).","journal-title":"Acta Biomater."},{"key":"2673_CR147","first-page":"286","volume":"20","author":"P Wu","year":"2023","unstructured":"Wu, P. et al. Maturation of induced pluripotent stem cell-derived cardiomyocytes and its therapeutic effect on myocardial infarction in mouse. Bioact. Mater. 20, 286\u2013305 (2023).","journal-title":"Bioact. Mater."},{"key":"2673_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101987","volume":"6","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Injectable hydrogel with miR-222-engineered extracellular vesicles ameliorates myocardial ischemic reperfusion injury via mechanotransduction. Cell Rep. Med. 6, 101987 (2025).","journal-title":"Cell Rep. Med."},{"key":"2673_CR149","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1124\/pharmrev.121.000381","volume":"74","author":"LM Lucas","year":"2022","unstructured":"Lucas, L. M. et al. The Yin and Yang of ERBB4: tumor suppressor and oncoprotein. Pharmacol. Rev. 74, 18\u201347 (2022).","journal-title":"Pharmacol. Rev."},{"key":"2673_CR150","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1377\/hlthaff.2024.00363","volume":"43","author":"KA Clifford","year":"2024","unstructured":"Clifford, K. A. et al. Small-molecule drugs offer comparable health benefits to biologics at lower costs. Health Aff. 43, 1546\u20131552 (2024).","journal-title":"Health Aff."},{"key":"2673_CR151","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ejheart.2007.04.003","volume":"9","author":"M Metra","year":"2007","unstructured":"Metra, M. et al. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 9, 684\u2013694 (2007).","journal-title":"Eur. J. Heart Fail."},{"key":"2673_CR152","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/ejhf.3264","volume":"26","author":"I Falc\u00e3o-Pires","year":"2024","unstructured":"Falc\u00e3o-Pires, I. et al. Mechanisms of myocardial reverse remodelling and its clinical significance: a scientific statement of the ESC Working Group on Myocardial Function. Eur. J. Heart Fail. 26, 1454\u20131479 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"2673_CR153","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41584-022-00797-1","volume":"18","author":"L Broderick","year":"2022","unstructured":"Broderick, L. & Hoffman, H. M. IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nat. Rev. Rheumatol. 18, 448\u2013463 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2673_CR154","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","volume":"122","author":"A Grebe","year":"2018","unstructured":"Grebe, A., Hoss, F. & Latz, E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ. Res. 122, 1722\u20131740 (2018).","journal-title":"Circ. Res."},{"key":"2673_CR155","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41569-020-0431-7","volume":"18","author":"DJ Tyrrell","year":"2021","unstructured":"Tyrrell, D. J. & Goldstein, D. R. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat. Rev. Cardiol. 18, 58\u201368 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"2673_CR156","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1093\/eurheartj\/ehz206","volume":"40","author":"T Christersdottir","year":"2019","unstructured":"Christersdottir, T. et al. Prevention of radiotherapy-induced arterial inflammation by interleukin-1 blockade. Eur. Heart J. 40, 2495\u20132503 (2019).","journal-title":"Eur. Heart J."},{"key":"2673_CR157","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/CIRCRESAHA.120.317685","volume":"128","author":"AR Perestrelo","year":"2021","unstructured":"Perestrelo, A. R. et al. Multiscale analysis of extracellular matrix remodeling in the failing heart. Circ. Res. 128, 24\u201338 (2021).","journal-title":"Circ. Res."},{"key":"2673_CR158","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202303957","volume":"13","author":"D Yin","year":"2024","unstructured":"Yin, D. et al. IL-37 modulates myocardial calcium handling via the p-STAT3\/SERCA2a axis in HF-related engineered human heart tissue. Adv. Health. Mater. 13, e2303957 (2024).","journal-title":"Adv. Health. Mater."},{"key":"2673_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108053","volume":"236","author":"S Toldo","year":"2022","unstructured":"Toldo, S. et al. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol. Ther. 236, 108053 (2022).","journal-title":"Pharmacol. Ther."},{"key":"2673_CR160","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.2147\/DDDT.S261119","volume":"18","author":"PK Vlachakis","year":"2024","unstructured":"Vlachakis, P. K. et al. Clinical utility of rilonacept for the treatment of recurrent pericarditis: design, development, and place in therapy. Drug Des. Dev. Ther. 18, 3939\u20133950 (2024).","journal-title":"Drug Des. Dev. Ther."},{"key":"2673_CR161","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1161\/CIRCULATIONAHA.124.069396","volume":"150","author":"A Abbate","year":"2024","unstructured":"Abbate, A. et al. Results of international, double-blind, randomized, placebo-controlled, phase IIa study of interleukin-1 blockade with RPH-104 (Goflikicept) in patients with ST-Segment-Elevation Myocardial Infarction (STEMI). Circulation 150, 580\u2013582 (2024).","journal-title":"Circulation"},{"key":"2673_CR162","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello, C. A., Simon, A. & van der Meer, J. W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11, 633\u2013652 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2673_CR163","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1177\/2047487319879534","volume":"27","author":"M Imazio","year":"2020","unstructured":"Imazio, M. et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. Eur. J. Prev. Cardiol. 27, 956\u2013964 (2020).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"2673_CR164","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/NEJMoa2027892","volume":"384","author":"AL Klein","year":"2021","unstructured":"Klein, A. L. et al. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N. Engl. J. Med. 384, 31\u201341 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR165","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1093\/eurheartj\/ehab452","volume":"43","author":"M Imazio","year":"2022","unstructured":"Imazio, M. et al. Anti-interleukin-1 agents for pericarditis: a primer for cardiologists. Eur. Heart J. 43, 2946\u20132957 (2022).","journal-title":"Eur. Heart J."},{"key":"2673_CR166","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032516","volume":"13","author":"M Imazio","year":"2024","unstructured":"Imazio, M. et al. Sustained pericarditis recurrence risk reduction with long-term rilonacept. J. Am. Heart Assoc. 13, e032516 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"2673_CR167","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jacc.2023.04.046","volume":"82","author":"VY Myachikova","year":"2023","unstructured":"Myachikova, V. Y. et al. Treatment of idiopathic recurrent pericarditis with Goflikicept: phase II\/III study results. J. Am. Coll. Cardiol. 82, 30\u201340 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR168","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamacardio.2022.2584","volume":"7","author":"S Kumar","year":"2022","unstructured":"Kumar, S. et al. Advances in imaging and targeted therapies for recurrent pericarditis: a review. JAMA Cardiol. 7, 975\u2013985 (2022).","journal-title":"JAMA Cardiol."},{"key":"2673_CR169","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41581-022-00621-9","volume":"18","author":"T Speer","year":"2022","unstructured":"Speer, T. et al. Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. Nat. Rev. Nephrol. 18, 762\u2013778 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"2673_CR170","first-page":"206","volume":"11","author":"N Katkenov","year":"2024","unstructured":"Katkenov, N. et al. Systematic review on the role of IL-6 and IL-1\u03b2 in cardiovascular diseases. J. Cardiovasc. Dev. Dis. 11, 206 (2024).","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"2673_CR171","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","volume":"126","author":"A Abbate","year":"2020","unstructured":"Abbate, A. et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ. Res. 126, 1260\u20131280 (2020).","journal-title":"Circ. Res."},{"key":"2673_CR172","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/FJC.0000000000001635","volume":"84","author":"A Abbate","year":"2024","unstructured":"Abbate, A. et al. Interleukin-1 blockade with RPH-104 (Goflikicept) in patients with ST-segment elevation myocardial infarction: secondary end points from an international, double-blind, randomized, placebo-controlled, phase 2a study. J. Cardiovasc Pharm. 84, 565\u2013577 (2024).","journal-title":"J. Cardiovasc Pharm."},{"key":"2673_CR173","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR174","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","volume":"391","author":"PM Ridker","year":"2018","unstructured":"Ridker, P. M. et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391, 319\u2013328 (2018).","journal-title":"Lancet"},{"key":"2673_CR175","doi-asserted-by":"publisher","first-page":"e002301","DOI":"10.1136\/openhrt-2023-002301","volume":"10","author":"S Woxholt","year":"2023","unstructured":"Woxholt, S. et al. Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab. Open Heart 10, e002301 (2023).","journal-title":"Open Heart"},{"key":"2673_CR176","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","volume":"77","author":"K Broch","year":"2021","unstructured":"Broch, K. et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 77, 1845\u20131855 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR177","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jjcc.2023.05.006","volume":"82","author":"Y Wada","year":"2023","unstructured":"Wada, Y. et al. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial. J. Cardiol. 82, 279\u2013285 (2023).","journal-title":"J. Cardiol."},{"key":"2673_CR178","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker, P. M. et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 2060\u20132069 (2021).","journal-title":"Lancet"},{"key":"2673_CR179","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/jamacardio.2022.4277","volume":"8","author":"NH Adamstein","year":"2023","unstructured":"Adamstein, N. H. et al. Association of interleukin 6 inhibition with ziltivekimab and the neutrophil-lymphocyte ratio: a secondary analysis of the RESCUE clinical trial. JAMA Cardiol. 8, 177\u2013181 (2023).","journal-title":"JAMA Cardiol."},{"key":"2673_CR180","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00125-021-05637-7","volume":"65","author":"KL Ho","year":"2022","unstructured":"Ho, K. L. et al. Metabolic, structural and biochemical changes in diabetes and the development of heart failure. Diabetologia 65, 411\u2013423 (2022).","journal-title":"Diabetologia"},{"key":"2673_CR181","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.acvd.2020.06.006","volume":"113","author":"S Battault","year":"2020","unstructured":"Battault, S. et al. Myocardial glucotoxicity: mechanisms and potential therapeutic targets. Arch. Cardiovasc. Dis. 113, 736\u2013748 (2020).","journal-title":"Arch. Cardiovasc. Dis."},{"key":"2673_CR182","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","volume":"43","author":"D von Lewinski","year":"2022","unstructured":"von Lewinski, D. et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur. Heart J. 43, 4421\u20134432 (2022).","journal-title":"Eur. Heart J."},{"key":"2673_CR183","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jchf.2023.02.007","volume":"11","author":"D Rodolico","year":"2023","unstructured":"Rodolico, D., Schiattarella, G. G. & Taegtmeyer, H. The lure of cardiac metabolism in the diagnosis, prevention, and treatment of heart failure. JACC Heart Fail. 11, 637\u2013645 (2023).","journal-title":"JACC Heart Fail."},{"key":"2673_CR184","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.3390\/ijms25094900","volume":"25","author":"AA Boshchenko","year":"2024","unstructured":"Boshchenko, A. A. et al. Peptides are cardioprotective drugs of the future: the receptor and signaling mechanisms of the cardioprotective effect of glucagon-like peptide-1 receptor agonists. Int. J. Mol. Sci. 25, 4900 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2673_CR185","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1111\/dom.14174","volume":"22","author":"JM Wilson","year":"2020","unstructured":"Wilson, J. M. et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes. Metab. 22, 2451\u20132459 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"2673_CR186","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR187","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR188","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503\u2013515 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR189","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","volume":"42","author":"BA McLean","year":"2021","unstructured":"McLean, B. A. et al. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr. Rev. 42, 101\u2013132 (2021).","journal-title":"Endocr. Rev."},{"key":"2673_CR190","doi-asserted-by":"publisher","first-page":"10173","DOI":"10.3390\/ijms251810173","volume":"25","author":"A Caturano","year":"2024","unstructured":"Caturano, A. et al. Advances in the insulin-heart axis: current therapies and future directions. Int. J. Mol. Sci. 25, 10173 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2673_CR191","first-page":"140","volume":"37","author":"M Almutairi","year":"2021","unstructured":"Almutairi, M. et al. The GLP-1 receptor agonist liraglutide increases myocardial glucose oxidation rates via indirect mechanisms and mitigates experimental diabetic cardiomyopathy. Can. J. Cardiol. 37, 140\u2013150 (2021).","journal-title":"Can. J. Cardiol."},{"key":"2673_CR192","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1161\/01.CIR.0000139339.85840.DD","volume":"110","author":"LA Nikolaidis","year":"2004","unstructured":"Nikolaidis, L. A. et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110, 955\u2013961 (2004).","journal-title":"Circulation"},{"key":"2673_CR193","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12933-020-01000-z","volume":"19","author":"V Sukumaran","year":"2020","unstructured":"Sukumaran, V. et al. Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet. Cardiovasc. Diabetol. 19, 24 (2020).","journal-title":"Cardiovasc. Diabetol."},{"key":"2673_CR194","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.7150\/thno.66456","volume":"12","author":"A Maiseyeu","year":"2022","unstructured":"Maiseyeu, A. et al. Plaque-targeted, proteolysis-resistant, activatable and MRI-visible nano-GLP-1 receptor agonist targets smooth muscle cell differentiation in atherosclerosis. Theranostics 12, 2741\u20132757 (2022).","journal-title":"Theranostics"},{"key":"2673_CR195","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1038\/s42255-024-01168-8","volume":"6","author":"AN Webster","year":"2024","unstructured":"Webster, A. N. et al. Molecular connectomics reveals a glucagon-like peptide 1-sensitive neural circuit for satiety. Nat. Metab. 6, 2354\u20132373 (2024).","journal-title":"Nat. Metab."},{"key":"2673_CR196","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.apsb.2023.11.020","volume":"14","author":"Q Zhao","year":"2024","unstructured":"Zhao, Q. et al. Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis. Acta Pharm. Sin. B 14, 1283\u20131301 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"2673_CR197","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1210\/endrev\/bnac018","volume":"44","author":"JM Yabut","year":"2023","unstructured":"Yabut, J. M. & Drucker, D. J. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr. Rev. 44, 14\u201332 (2023).","journal-title":"Endocr. Rev."},{"key":"2673_CR198","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher, J. R. & Drucker, D. J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat. Rev. Cardiol. 20, 463\u2013474 (2023).","journal-title":"Nat. Rev. Cardiol."},{"key":"2673_CR199","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.3390\/ijms25052484","volume":"25","author":"G Gallo","year":"2024","unstructured":"Gallo, G. & Volpe, M. Potential mechanisms of the protective effects of the cardiometabolic drugs type-2 sodium-glucose transporter inhibitors and glucagon-like peptide-1 receptor agonists in heart failure. Int. J. Mol. Sci. 25, 2484 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2673_CR200","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121\u2013130 (2019).","journal-title":"Lancet"},{"key":"2673_CR201","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein, H. C. et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394, 131\u2013138 (2019).","journal-title":"Lancet"},{"key":"2673_CR202","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1002\/ejhf.2670","volume":"24","author":"KRH Branch","year":"2022","unstructured":"Branch, K. R. H. et al. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial. Eur. J. Heart Fail. 24, 1805\u20131812 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"2673_CR203","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.2337\/dc22-2397","volume":"46","author":"HC Gerstein","year":"2023","unstructured":"Gerstein, H. C. et al. Biomarker changes associated with both dulaglutide and cardiovascular events in the REWIND randomized controlled trial: a nested case-control post hoc analysis. Diabetes Care 46, 1046\u20131051 (2023).","journal-title":"Diabetes Care"},{"key":"2673_CR204","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.123.066604","volume":"149","author":"JB Green","year":"2024","unstructured":"Green, J. B. et al. Cardiovascular outcomes in GRADE (glycemia reduction approaches in type 2 diabetes: a comparative effectiveness study). Circulation 149, 993\u20131003 (2024).","journal-title":"Circulation"},{"key":"2673_CR205","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.2337\/dc19-2251","volume":"43","author":"JB Buse","year":"2020","unstructured":"Buse, J. B. et al. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial. Diabetes Care 43, 1546\u20131552 (2020).","journal-title":"Diabetes Care"},{"key":"2673_CR206","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","volume":"138","author":"JFE Mann","year":"2018","unstructured":"Mann, J. F. E. et al. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. Circulation 138, 2908\u20132918 (2018).","journal-title":"Circulation"},{"key":"2673_CR207","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR208","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/eurheartj\/ehae613","volume":"46","author":"KW Mahaffey","year":"2025","unstructured":"Mahaffey, K. W. et al. Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. Eur. Heart J. 46, 1096\u20131108 (2025).","journal-title":"Eur. Heart J."},{"key":"2673_CR209","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod, M. N. et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet 404, 949\u2013961 (2024).","journal-title":"Lancet"},{"key":"2673_CR210","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40265-023-01992-4","volume":"84","author":"NL France","year":"2024","unstructured":"France, N. L. & Syed, Y. Y. Tirzepatide: a review in type 2 diabetes. Drugs 84, 227\u2013238 (2024).","journal-title":"Drugs"},{"key":"2673_CR211","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205\u2013216 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR212","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer, M. et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 392, 427\u2013437 (2025).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR213","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","volume":"31","author":"BA Borlaug","year":"2025","unstructured":"Borlaug, B. A. et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat. Med. 31, 544\u2013551 (2025).","journal-title":"Nat. Med."},{"key":"2673_CR214","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown, E., Heerspink, H. J. L., Cuthbertson, D. J. & Wilding, J. P. H. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 398, 262\u2013276 (2021).","journal-title":"Lancet"},{"key":"2673_CR215","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089\u20131098 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR216","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A. et al. AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 79, e263\u2013e421 (2022). 2022.","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR217","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41569-024-00997-0","volume":"21","author":"B Bozkurt","year":"2024","unstructured":"Bozkurt, B. Contemporary pharmacological treatment and management of heart failure. Nat. Rev. Cardiol. 21, 545\u2013555 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"2673_CR218","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451\u20131461 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR219","doi-asserted-by":"publisher","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","volume":"3","author":"S James","year":"2024","unstructured":"James, S. et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 3, EVIDoa2300286 (2024).","journal-title":"NEJM Evid."},{"key":"2673_CR220","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","volume":"390","author":"J Butler","year":"2024","unstructured":"Butler, J. et al. Empagliflozin after acute myocardial infarction. N. Engl. J. Med. 390, 1455\u20131466 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR221","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s11427-017-9223-x","volume":"61","author":"X Du","year":"2018","unstructured":"Du, X. Post-infarct cardiac injury, protection and repair: roles of non-cardiomyocyte multicellular and acellular components. Sci. China Life Sci. 61, 266\u2013276 (2018).","journal-title":"Sci. China Life Sci."},{"key":"2673_CR222","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.addr.2021.03.014","volume":"173","author":"MA Borrelli","year":"2021","unstructured":"Borrelli, M. A., Turnquist, H. R. & Little, S. R. Biologics and their delivery systems: trends in myocardial infarction. Adv. Drug Deliv. Rev. 173, 181\u2013215 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2673_CR223","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2090","volume":"3","author":"A Ucar","year":"2012","unstructured":"Ucar, A. et al. The miRNA-212\/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun. 3, 1078 (2012).","journal-title":"Nat. Commun."},{"key":"2673_CR224","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14349-2","volume":"11","author":"A Foinquinos","year":"2020","unstructured":"Foinquinos, A. et al. Preclinical development of a miR-132 inhibitor for heart failure treatment. Nat. Commun. 11, 633 (2020).","journal-title":"Nat. Commun."},{"key":"2673_CR225","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/eurheartj\/ehaa791","volume":"42","author":"S Batkai","year":"2021","unstructured":"Batkai, S. et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. Eur. Heart J. 42, 192\u2013201 (2021).","journal-title":"Eur. Heart J."},{"key":"2673_CR226","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","volume":"42","author":"J T\u00e4ubel","year":"2021","unstructured":"T\u00e4ubel, J. et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur. Heart J. 42, 178\u2013188 (2021).","journal-title":"Eur. Heart J."},{"key":"2673_CR227","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.118.034598","volume":"138","author":"EM Rogg","year":"2018","unstructured":"Rogg, E. M. et al. Analysis of cell type-specific effects of MicroRNA-92a provides novel insights into target regulation and mechanism of action. Circulation 138, 2545\u20132558 (2018).","journal-title":"Circulation"},{"key":"2673_CR228","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1089\/nat.2020.0871","volume":"30","author":"WT Abplanalp","year":"2020","unstructured":"Abplanalp, W. T. et al. Efficiency and target derepression of anti-miR-92a: results of a first in human study. Nucleic Acid Ther. 30, 335\u2013345 (2020).","journal-title":"Nucleic Acid Ther."},{"key":"2673_CR229","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41569-020-00504-1","volume":"18","author":"B L\u00f3pez","year":"2021","unstructured":"L\u00f3pez, B. et al. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nat. Rev. Cardiol. 18, 479\u2013498 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"2673_CR230","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1161\/01.CIR.104.3.286","volume":"104","author":"B L\u00f3pez","year":"2001","unstructured":"L\u00f3pez, B. et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 104, 286\u2013291 (2001).","journal-title":"Circulation"},{"key":"2673_CR231","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1161\/01.CIR.91.9.2353","volume":"91","author":"B Villari","year":"1995","unstructured":"Villari, B. et al. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation 91, 2353\u20132358 (1995).","journal-title":"Circulation"},{"key":"2673_CR232","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1111\/jcmm.14074","volume":"23","author":"H Schilter","year":"2019","unstructured":"Schilter, H. et al. The lysyl oxidase like 2\/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis. J. Cell Mol. Med. 23, 1759\u20131770 (2019).","journal-title":"J. Cell Mol. Med."},{"key":"2673_CR233","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-2600(16)30421-0","volume":"5","author":"G Raghu","year":"2017","unstructured":"Raghu, G. et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir. Med. 5, 22\u201332 (2017).","journal-title":"Lancet Respir. Med."},{"key":"2673_CR234","doi-asserted-by":"publisher","first-page":"101636","DOI":"10.1016\/j.disamonth.2023.101636","volume":"70","author":"N Vora","year":"2024","unstructured":"Vora, N. et al. Gene Ther. for heart failure: a novel treatment for the age old disease. Dis. Mon. 70, 101636 (2024).","journal-title":"Dis. Mon."},{"key":"2673_CR235","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1161\/CIRCULATIONAHA.122.062885","volume":"147","author":"T Hitsumoto","year":"2023","unstructured":"Hitsumoto, T. et al. Restoration of cardiac myosin light chain kinase ameliorates systolic dysfunction by reducing superrelaxed myosin. Circulation 147, 1902\u20131918 (2023).","journal-title":"Circulation"},{"key":"2673_CR236","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jacbts.2023.07.013","volume":"9","author":"A Garg","year":"2024","unstructured":"Garg, A., Lavine, K. J. & Greenberg, M. J. Assessing cardiac contractility from single molecules to whole hearts. JACC Basic Transl. Sci. 9, 414\u2013439 (2024).","journal-title":"JACC Basic Transl. Sci."},{"key":"2673_CR237","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/eurjhf\/hfs119","volume":"14","author":"PA van der Zwaag","year":"2012","unstructured":"van der Zwaag, P. A. et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur. J. Heart Fail. 14, 1199\u20131207 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"2673_CR238","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1600-6143.2006.01241.x","volume":"6","author":"R St\u00fcdeli","year":"2006","unstructured":"St\u00fcdeli, R. et al. Diastolic dysfunction in human cardiac allografts is related with reduced SERCA2a gene expression. Am. J. Transpl. 6, 775\u2013782 (2006).","journal-title":"Am. J. Transpl."},{"key":"2673_CR239","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1073\/pnas.0510519103","volume":"103","author":"K Haghighi","year":"2006","unstructured":"Haghighi, K. et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl. Acad. Sci. USA 103, 1388\u20131393 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2673_CR240","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.jacc.2007.12.014","volume":"51","author":"Y Kawase","year":"2008","unstructured":"Kawase, Y. et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J. Am. Coll. Cardiol. 51, 1112\u20131119 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR241","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1161\/hc3601.095574","volume":"104","author":"F del Monte","year":"2001","unstructured":"del Monte, F. et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 104, 1424\u20131429 (2001).","journal-title":"Circulation"},{"key":"2673_CR242","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1161\/CIRCHEARTFAILURE.109.891184","volume":"3","author":"R Beeri","year":"2010","unstructured":"Beeri, R. et al. Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. Circ. Heart Fail. 3, 627\u2013634 (2010).","journal-title":"Circ. Heart Fail."},{"key":"2673_CR243","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","volume":"124","author":"M Jessup","year":"2011","unstructured":"Jessup, M. et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124, 304\u2013313 (2011).","journal-title":"Circulation"},{"key":"2673_CR244","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","volume":"387","author":"B Greenberg","year":"2016","unstructured":"Greenberg, B. et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet 387, 1178\u20131186 (2016).","journal-title":"Lancet"},{"key":"2673_CR245","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1002\/ejhf.826","volume":"19","author":"JS Hulot","year":"2017","unstructured":"Hulot, J. S. et al. Effect of intracoronary administration of AAV1\/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial. Eur. J. Heart Fail. 19, 1534\u20131541 (2017).","journal-title":"Eur. J. Heart Fail."},{"key":"2673_CR246","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.omtm.2023.08.010","volume":"30","author":"CY Kok","year":"2023","unstructured":"Kok, C. Y. et al. Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes. Mol. Ther. Methods Clin. Dev. 30, 459\u2013473 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2673_CR247","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"JH Wang","year":"2024","unstructured":"Wang, J. H. et al. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct. Target. Ther. 9, 78 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2673_CR248","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nbt.1599","volume":"28","author":"A Asokan","year":"2010","unstructured":"Asokan, A. et al. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat. Biotechnol. 28, 79\u201382 (2010).","journal-title":"Nat. Biotechnol."},{"key":"2673_CR249","first-page":"23484","volume":"148","author":"TD Henry","year":"2023","unstructured":"Henry, T. D. et al. Phase 1 gene therapy trial in patients with advanced heart failure using anovel cardiotropic AAV vector targeting protein phosphatase inhibitor-1. Circulation 148, 23484 (2023).","journal-title":"Circulation"},{"key":"2673_CR250","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1161\/01.CIR.0000136033.21777.4D","volume":"110","author":"NC Lai","year":"2004","unstructured":"Lai, N. C. et al. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation 110, 330\u2013336 (2004).","journal-title":"Circulation"},{"key":"2673_CR251","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamacardio.2016.0008","volume":"1","author":"HK Hammond","year":"2016","unstructured":"Hammond, H. K. et al. Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial. JAMA Cardiol. 1, 163\u2013171 (2016).","journal-title":"JAMA Cardiol."},{"key":"2673_CR252","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ahj.2018.04.005","volume":"201","author":"WF Penny","year":"2018","unstructured":"Penny, W. F. et al. Design of a phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial. Am. Heart J. 201, 111\u2013116 (2018).","journal-title":"Am. Heart J."},{"key":"2673_CR253","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jacbts.2024.07.006","volume":"9","author":"MD Martens","year":"2024","unstructured":"Martens, M. D. et al. Semaglutide reduces cardiomyocyte size and cardiac mass in lean and obese mice. JACC Basic Transl. Sci. 9, 1429\u20131431 (2024).","journal-title":"JACC Basic Transl. Sci."},{"key":"2673_CR254","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3516","volume":"27","author":"S Van Linthout","year":"2025","unstructured":"Van Linthout, S. et al. State of the art and perspectives of gene therapy in heart failure. A scientific statement of the Heart Failure Association of the ESC, the ESC Council on Cardiovascular Genomics and the ESC Working Group on Myocardial & Pericardial Diseases. Eur. J. Heart Fail. 27, 5\u201325 (2025).","journal-title":"Eur. J. Heart Fail."},{"key":"2673_CR255","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg, F. L. & Maurer, M. S. Cardiac amyloidosis due to transthyretin protein: a review. JAMA 331, 778\u2013791 (2024).","journal-title":"JAMA"},{"key":"2673_CR256","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41569-022-00682-0","volume":"19","author":"SJ Lehman","year":"2022","unstructured":"Lehman, S. J., Crocini, C. & Leinwand, L. A. Targeting the sarcomere in inherited cardiomyopathies. Nat. Rev. Cardiol. 19, 353\u2013363 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"2673_CR257","first-page":"777","volume":"40","author":"ED Paratz","year":"2024","unstructured":"Paratz, E. D. et al. Gene therapy in cardiology: is a cure for hypertrophic cardiomyopathy on the horizon? Can. J. Cardiol. 40, 777\u2013788 (2024).","journal-title":"Can. J. Cardiol."},{"key":"2673_CR258","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.119.002579","volume":"12","author":"ED Carruth","year":"2019","unstructured":"Carruth, E. D. et al. Prevalence and electronic health record-based phenotype of loss-of-function genetic variants in arrhythmogenic right ventricular cardiomyopathy-associated genes. Circ. Genom. Precis. Med. 12, e002579 (2019).","journal-title":"Circ. Genom. Precis. Med."},{"key":"2673_CR259","doi-asserted-by":"publisher","first-page":"e133782","DOI":"10.1172\/jci.insight.133782","volume":"5","author":"AS Helms","year":"2020","unstructured":"Helms, A. S. et al. Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy. JCI Insight 5, e133782 (2020).","journal-title":"JCI Insight"},{"key":"2673_CR260","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5334\/gh.1262","volume":"18","author":"D Brito","year":"2023","unstructured":"Brito, D. et al. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Glob. Heart 18, 59 (2023).","journal-title":"Glob. Heart"},{"key":"2673_CR261","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg, F. L. et al. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73, 2872\u20132891 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR262","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1073\/pnas.1317488111","volume":"111","author":"PP Mangione","year":"2014","unstructured":"Mangione, P. P. et al. Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc. Natl. Acad. Sci. USA 111, 1539\u20131544 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2673_CR263","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","volume":"7","author":"RM Witteles","year":"2019","unstructured":"Witteles, R. M. et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 7, 709\u2013716 (2019).","journal-title":"JACC Heart Fail."},{"key":"2673_CR264","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou, A. et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation 146, 1657\u20131670 (2022).","journal-title":"Circulation"},{"key":"2673_CR265","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","volume":"6","author":"OF AbouEzzeddine","year":"2021","unstructured":"AbouEzzeddine, O. F. et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol. 6, 1267\u20131274 (2021).","journal-title":"JAMA Cardiol."},{"key":"2673_CR266","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1177\/2047487319877708","volume":"27","author":"G Vergaro","year":"2020","unstructured":"Vergaro, G. et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. Eur. J. Prev. Cardiol. 27, 1806\u20131815 (2020).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"2673_CR267","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson, M. M. et al. ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J. Am. Coll. Cardiol. 81, 1076\u20131126 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR268","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","volume":"23","author":"GT Giblin","year":"2022","unstructured":"Giblin, G. T. et al. Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis. Eur. Heart J. Cardiovasc. Imaging 23, 1029\u20131039 (2022).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"2673_CR269","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott, P. et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ. Heart Fail. 15, e008193 (2022).","journal-title":"Circ. Heart Fail."},{"key":"2673_CR270","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40259-022-00550-w","volume":"36","author":"M Nuvolone","year":"2022","unstructured":"Nuvolone, M., Nevone, A. & Merlini, G. Targeting amyloid fibrils by passive immunotherapy in systemic amyloidosis. BioDrugs 36, 591\u2013608 (2022).","journal-title":"BioDrugs"},{"key":"2673_CR271","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","volume":"23","author":"JN Higaki","year":"2016","unstructured":"Higaki, J. N. et al. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid 23, 86\u201397 (2016).","journal-title":"Amyloid"},{"key":"2673_CR272","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23274-x","volume":"12","author":"A Michalon","year":"2021","unstructured":"Michalon, A. et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat. Commun. 12, 3142 (2021).","journal-title":"Nat. Commun."},{"key":"2673_CR273","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia, P. et al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N. Engl. J. Med. 389, 239\u2013250 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR274","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/cpt.3455","volume":"117","author":"A Michalon","year":"2025","unstructured":"Michalon, A. et al. Prediction of cardiac ATTR depletion by NI006 (ALXN2220) using mechanistic PK\/PD modeling. Clin. Pharmacol. Ther. 117, 261\u2013269 (2025).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2673_CR275","doi-asserted-by":"publisher","first-page":"B79","DOI":"10.1093\/eurheartjsupp\/suad079","volume":"25","author":"M Emdin","year":"2023","unstructured":"Emdin, M. et al. Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis. Eur. Heart J. Suppl. 25, B79\u2013b84 (2023).","journal-title":"Eur. Heart J. Suppl."},{"key":"2673_CR276","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/FJC.0000000000001478","volume":"82","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. Recent progress in the development and clinical application of new drugs for transthyretin cardiac amyloidosis. J. Cardiovasc. Pharmacol. 82, 427\u2013437 (2023).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2673_CR277","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho, T. et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819\u2013829 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR278","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer, M. S. et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N. Engl. J. Med. 389, 1553\u20131565 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR279","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","volume":"28","author":"AD Springer","year":"2018","unstructured":"Springer, A. D. & Dowdy, S. F. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 28, 109\u2013118 (2018).","journal-title":"Nucleic Acid Ther."},{"key":"2673_CR280","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2024","unstructured":"Fontana, M. et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N. Engl. J Med. 392, 33\u201344 (2024).","journal-title":"N. Engl. J Med."},{"key":"2673_CR281","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","volume":"78","author":"SJ Keam","year":"2018","unstructured":"Keam, S. J. Inotersen: first global approval. Drugs 78, 1371\u20131376 (2018).","journal-title":"Drugs"},{"key":"2673_CR282","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson, M. D. et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N. Engl. J. Med 379, 22\u201331 (2018).","journal-title":"N. Engl. J. Med"},{"key":"2673_CR283","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ehf2.13154","volume":"8","author":"NJ Viney","year":"2021","unstructured":"Viney, N. J. et al. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail. 8, 652\u2013661 (2021).","journal-title":"ESC Heart Fail."},{"key":"2673_CR284","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho, T. et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA 330, 1448\u20131458 (2023).","journal-title":"JAMA"},{"key":"2673_CR285","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-024-02008-5","volume":"84","author":"T Nie","year":"2024","unstructured":"Nie, T. Eplontersen: first approval. Drugs 84, 473\u2013478 (2024).","journal-title":"Drugs"},{"key":"2673_CR286","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.cardfail.2023.11.016","volume":"30","author":"A Masri","year":"2024","unstructured":"Masri, A. et al. Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis. J. Card. Fail. 30, 973\u2013980 (2024).","journal-title":"J. Card. Fail."},{"key":"2673_CR287","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1074\/jbc.M008091200","volume":"276","author":"AM van Bennekum","year":"2001","unstructured":"van Bennekum, A. M. et al. Biochemical basis for depressed serum retinol levels in transthyretin-deficient mice. J. Biol. Chem. 276, 1107\u20131113 (2001).","journal-title":"J. Biol. Chem."},{"key":"2673_CR288","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz, M. A. et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J. Am. Coll. Cardiol. 66, 2451\u20132466 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR289","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med"},{"key":"2673_CR290","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMc1701400","volume":"376","author":"S Ganatra","year":"2017","unstructured":"Ganatra, S. & Sharma, A. Arrhythmogenic right ventricular cardiomyopathy. N. Engl. J. Med. 376, 1489 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR291","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJM198801213180301","volume":"318","author":"G Thiene","year":"1988","unstructured":"Thiene, G. et al. Right ventricular cardiomyopathy and sudden death in young people. N. Engl. J. Med. 318, 129\u2013133 (1988).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR292","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1136\/heartjnl-2021-319113","volume":"108","author":"LP Bosman","year":"2022","unstructured":"Bosman, L. P. & Te Riele, A. Arrhythmogenic right ventricular cardiomyopathy: a focused update on diagnosis and risk stratification. Heart 108, 90\u201397 (2022).","journal-title":"Heart"},{"key":"2673_CR293","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jacbts.2021.07.012","volume":"7","author":"AS Helms","year":"2022","unstructured":"Helms, A. S., Thompson, A. D. & Day, S. M. Translation of new and emerging therapies for genetic cardiomyopathies. JACC Basic Transl. Sci. 7, 70\u201383 (2022).","journal-title":"JACC Basic Transl. Sci."},{"key":"2673_CR294","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/eurheartj\/ehu509","volume":"36","author":"A Bhonsale","year":"2015","unstructured":"Bhonsale, A. et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia\/cardiomyopathy-associated mutation carriers. Eur. Heart J. 36, 847\u2013855 (2015).","journal-title":"Eur. Heart J."},{"key":"2673_CR295","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/S0735-1097(01)01568-6","volume":"38","author":"N Protonotarios","year":"2001","unstructured":"Protonotarios, N. et al. Genotype-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (Naxos disease) caused by a deletion in plakoglobin. J. Am. Coll. Cardiol. 38, 1477\u20131484 (2001).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR296","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/ng1461","volume":"36","author":"B Gerull","year":"2004","unstructured":"Gerull, B. et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat. Genet. 36, 1162\u20131164 (2004).","journal-title":"Nat. Genet."},{"key":"2673_CR297","volume":"17","author":"CJM van Opbergen","year":"2024","unstructured":"van Opbergen, C. J. M. et al. AAV-mediated delivery of plakophilin-2a arrests progression of arrhythmogenic right ventricular cardiomyopathy in murine hearts: preclinical evidence supporting gene therapy in humans. Circ. Genom. Precis. Med. 17, e004305 (2024).","journal-title":"Circ. Genom. Precis. Med."},{"key":"2673_CR298","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s43856-024-00450-w","volume":"4","author":"I Wu","year":"2024","unstructured":"Wu, I. et al. AAV9:PKP2 improves heart function and survival in a Pkp2-deficient mouse model of arrhythmogenic right ventricular cardiomyopathy. Commun. Med. 4, 38 (2024).","journal-title":"Commun. Med."},{"key":"2673_CR299","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s44161-023-00378-9","volume":"2","author":"E Kyriakopoulou","year":"2023","unstructured":"Kyriakopoulou, E. et al. Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy. Nat. Cardiovasc. Res. 2, 1262\u20131276 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"2673_CR300","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s44161-023-00370-3","volume":"2","author":"WH Bradford","year":"2023","unstructured":"Bradford, W. H. et al. Plakophilin\u20092 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics. Nat. Cardiovasc. Res. 2, 1246\u20131261 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"2673_CR301","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/biomedicines12061351","volume":"12","author":"J Mundisugih","year":"2024","unstructured":"Mundisugih, J., Ravindran, D. & Kizana, E. Exploring the therapeutic potential of gene therapy in arrhythmogenic right ventricular cardiomyopathy. Biomedicines. 12, 1351 (2024).","journal-title":"Biomedicines."},{"key":"2673_CR302","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/hmg\/ddab127","volume":"30","author":"M Shiba","year":"2021","unstructured":"Shiba, M. et al. Phenotypic recapitulation and correction of desmoglein-2-deficient cardiomyopathy using human-induced pluripotent stem cell-derived cardiomyocytes. Hum. Mol. Genet. 30, 1384\u20131397 (2021).","journal-title":"Hum. Mol. Genet."},{"key":"2673_CR303","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1093\/cvr\/cvac021","volume":"118","author":"J Dave","year":"2022","unstructured":"Dave, J. et al. Gene editing reverses arrhythmia susceptibility in humanized PLN-R14del mice: modelling a European cardiomyopathy with global impact. Cardiovasc. Res. 118, 3140\u20133150 (2022).","journal-title":"Cardiovasc. Res."},{"key":"2673_CR304","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41392-024-01750-2","volume":"9","author":"Y Zheng","year":"2024","unstructured":"Zheng, Y. et al. Precise genome-editing in human diseases: mechanisms, strategies and applications. Signal Transduct. Target. Ther. 9, 47 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2673_CR305","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian, C., Ingles, J., Maron, M. S. & Maron, B. J. New perspectives on the prevalence of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 65, 1249\u20131254 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR306","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen, S. R. et al. AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 76, e159\u2013e240 (2020). 2020.","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR307","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1093\/eurheartj\/ehae421","volume":"45","author":"LR Lopes","year":"2024","unstructured":"Lopes, L. R., Ho, C. Y. & Elliott, P. M. Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice. Eur. Heart J. 45, 2727\u20132734 (2024).","journal-title":"Eur. Heart J."},{"key":"2673_CR308","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/heartjnl-2020-316798","volume":"107","author":"M Ahluwalia","year":"2021","unstructured":"Ahluwalia, M. & Ho, C. Y. Cardiovascular genetics: the role of genetic testing in diagnosis and management of patients with hypertrophic cardiomyopathy. Heart 107, 183\u2013189 (2021).","journal-title":"Heart"},{"key":"2673_CR309","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jamacardio.2022.1061","volume":"7","author":"KJ Biddinger","year":"2022","unstructured":"Biddinger, K. J. et al. Rare and common genetic variation underlying the risk of hypertrophic cardiomyopathy in a national biobank. JAMA Cardiol. 7, 715\u2013722 (2022).","journal-title":"JAMA Cardiol."},{"key":"2673_CR310","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1161\/CIRCRESAHA.109.202440","volume":"105","author":"S Marston","year":"2009","unstructured":"Marston, S. et al. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ. Res. 105, 219\u2013222 (2009).","journal-title":"Circ. Res."},{"key":"2673_CR311","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41587-023-01745-4","volume":"41","author":"C Sheridan","year":"2023","unstructured":"Sheridan, C. Genetic medicines aim straight for the heart. Nat. Biotechnol. 41, 435\u2013437 (2023).","journal-title":"Nat. Biotechnol."},{"key":"2673_CR312","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/hrt.2003.029504","volume":"90","author":"P Charron","year":"2004","unstructured":"Charron, P. et al. Danon\u2019s disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart 90, 842\u2013846 (2004).","journal-title":"Heart"},{"key":"2673_CR313","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1080\/15548627.2023.2235196","volume":"19","author":"L Qiao","year":"2023","unstructured":"Qiao, L. et al. LAMP2A, LAMP2B and LAMP2C: similar structures, divergent roles. Autophagy 19, 2837\u20132852 (2023).","journal-title":"Autophagy"},{"key":"2673_CR314","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jacc.2023.08.014","volume":"82","author":"KN Hong","year":"2023","unstructured":"Hong, K. N. et al. International consensus on differential diagnosis and management of patients with Danon disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 82, 1628\u20131647 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR315","doi-asserted-by":"publisher","first-page":"eaax1744","DOI":"10.1126\/scitranslmed.aax1744","volume":"12","author":"AM Manso","year":"2020","unstructured":"Manso, A. M. et al. Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorg and ysfunction in a murine model of Danon disease. Sci. Transl. Med. 12, eaax1744 (2020).","journal-title":"Sci. Transl. Med."},{"key":"2673_CR316","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.cardfail.2022.10.021","volume":"29","author":"J Rossano","year":"2023","unstructured":"Rossano, J. et al. Safety profile of the first pediatric cardiomyopathy gene therapy trial: RP-A501 (AAV9:LAMP2B) for Danon disease. J. Card. Fail. 29, 554 (2023).","journal-title":"J. Card. Fail."},{"key":"2673_CR317","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1056\/NEJMoa2412392","volume":"392","author":"B Greenberg","year":"2025","unstructured":"Greenberg, B. et al. Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease. N. Engl. J. Med. 392, 972\u2013983 (2025).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR318","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","volume":"29","author":"D Reichart","year":"2023","unstructured":"Reichart, D. et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat. Med. 29, 412\u2013421 (2023).","journal-title":"Nat. Med."},{"key":"2673_CR319","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","volume":"29","author":"AC Chai","year":"2023","unstructured":"Chai, A. C. et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nat. Med. 29, 401\u2013411 (2023).","journal-title":"Nat. Med."},{"key":"2673_CR320","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41434-023-00384-3","volume":"30","author":"J Nie","year":"2023","unstructured":"Nie, J. et al. Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy. Gene Ther. 30, 520\u2013527 (2023).","journal-title":"Gene Ther."},{"key":"2673_CR321","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.cell.2021.03.025","volume":"184","author":"JK Nu\u00f1ez","year":"2021","unstructured":"Nu\u00f1ez, J. K. et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell 184, 2503\u20132519.e2517 (2021).","journal-title":"Cell"},{"key":"2673_CR322","doi-asserted-by":"publisher","first-page":"ehae666.1983","DOI":"10.1093\/eurheartj\/ehae666.1983","volume":"45","author":"K Guha","year":"2024","unstructured":"Guha, K. et al. Patient characteristics and incidence of cardiac amyloidosis: an observational study in the UK clinical setting using electronic health records. Eur. Heart J. 45, ehae666.1983 (2024).","journal-title":"Eur. Heart J."},{"key":"2673_CR323","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1152\/physrev.00041.2022","volume":"104","author":"ER Drury","year":"2024","unstructured":"Drury, E. R., Wu, J., Gigliotti, J. C. & Le, T. H. Sex differences in blood pressure regulation and hypertension: renal, hemodynamic, and hormonal mechanisms. Physiol. Rev. 104, 199\u2013251 (2024).","journal-title":"Physiol. Rev."},{"key":"2673_CR324","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","volume":"11","author":"BA Borlaug","year":"2014","unstructured":"Borlaug, B. A. The pathophysiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 11, 507\u2013515 (2014).","journal-title":"Nat. Rev. Cardiol."},{"key":"2673_CR325","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.tem.2024.11.004","volume":"36","author":"KM Citrin","year":"2025","unstructured":"Citrin, K. M., Chaube, B., Fern\u00e1ndez-Hernando, C. & Su\u00e1rez, Y. Intracellular endothelial cell metabolism in vascular function and dysfunction. Trends Endocrinol. Metab. 36, 744\u2013755 (2025).","journal-title":"Trends Endocrinol. Metab."},{"key":"2673_CR326","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","volume":"98","author":"SJ Forrester","year":"2018","unstructured":"Forrester, S. J. et al. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol. Rev. 98, 1627\u20131738 (2018).","journal-title":"Physiol. Rev."},{"key":"2673_CR327","doi-asserted-by":"publisher","first-page":"105943","DOI":"10.1016\/j.phrs.2021.105943","volume":"174","author":"A Lymperopoulos","year":"2021","unstructured":"Lymperopoulos, A. et al. Cardiovascular angiotensin II type 1 receptor biased signaling: Focus on non-Gq-, non-\u03b2arrestin-dependent signaling. Pharm. Res. 174, 105943 (2021).","journal-title":"Pharm. Res."},{"key":"2673_CR328","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia, G. et al. ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J. Hypertens. 41, 1874\u20132071 (2023). 2023.","journal-title":"J. Hypertens."},{"key":"2673_CR329","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejim.2023.06.008","volume":"115","author":"M Kanbay","year":"2023","unstructured":"Kanbay, M. et al. Future treatments in hypertension: can we meet the unmet needs of patients? Eur. J. Intern. Med. 115, 18\u201328 (2023).","journal-title":"Eur. J. Intern. Med."},{"key":"2673_CR330","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jama.2024.0728","volume":"331","author":"GL Bakris","year":"2024","unstructured":"Bakris, G. L. et al. RNA interference with Zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial. JAMA 331, 740\u2013749 (2024).","journal-title":"JAMA"},{"key":"2673_CR331","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacbts.2021.04.004","volume":"6","author":"ES Morgan","year":"2021","unstructured":"Morgan, E. S. et al. Antisense inhibition of angiotensinogen with IONIS-AGT-L(Rx): results of phase 1 and phase 2 studies. JACC Basic Transl. Sci. 6, 485\u2013496 (2021).","journal-title":"JACC Basic Transl. Sci."},{"key":"2673_CR332","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1161\/HYPERTENSIONAHA.122.18731","volume":"79","author":"EO Cruz-L\u00f3pez","year":"2022","unstructured":"Cruz-L\u00f3pez, E. O. et al. Angiotensinogen suppression: a new tool to treat cardiovascular and renal disease. Hypertension 79, 2115\u20132126 (2022).","journal-title":"Hypertension"},{"key":"2673_CR333","first-page":"A10974","volume":"144","author":"S Huang","year":"2021","unstructured":"Huang, S. et al. Abstract 10974: durable reductions in circulating angiotensinogen and blood pressure six months after single doses of ALN-AGT, an RNA interference therapeutic targeting hepatic angiotensinogen synthesis, in hypertensive patients. Circulation 144, A10974\u2013A10974 (2021).","journal-title":"Circulation"},{"key":"2673_CR334","first-page":"210","volume":"150","author":"MSB Faheem","year":"2025","unstructured":"Faheem, M. S. B. Zilebesiran: a potential life-altering remedy for hypertensive patients. Cardiology 150, 210\u2013211 (2025).","journal-title":"Cardiology"},{"key":"2673_CR335","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.medj.2024.04.001","volume":"5","author":"KE Wulczyn","year":"2024","unstructured":"Wulczyn, K. E. & Rhee, E. P. siRNA takes a jab at hypertension. Med 5, 383\u2013385 (2024).","journal-title":"Med"},{"key":"2673_CR336","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.117.09755","volume":"70","author":"AE Mullick","year":"2017","unstructured":"Mullick, A. E. et al. Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury. Hypertension 70, 566\u2013576 (2017).","journal-title":"Hypertension"},{"key":"2673_CR337","doi-asserted-by":"publisher","first-page":"A17395","DOI":"10.1161\/circ.148.suppl_1.17395","volume":"148","author":"E Morgan","year":"2023","unstructured":"Morgan, E. et al. Abstract 17395: effect of ION904, an antisense inhibitor of angiotensinogen production: results of phase 1 and phase 2 pilot studies. Circulation 148, A17395 (2023).","journal-title":"Circulation"},{"key":"2673_CR338","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1161\/HYPERTENSIONAHA.121.18114","volume":"79","author":"T Tokudome","year":"2022","unstructured":"Tokudome, T. et al. Endothelial natriuretic peptide receptor 1 play crucial role for acute and chronic blood pressure regulation by atrial natriuretic peptide. Hypertension 79, 1409\u20131422 (2022).","journal-title":"Hypertension"},{"key":"2673_CR339","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1161\/01.ATV.0000084826.86349.1D","volume":"23","author":"M Schmitt","year":"2003","unstructured":"Schmitt, M. et al. Atrial natriuretic peptide regulates regional vascular volume and venous tone in humans. Arterioscler. Thromb. Vasc. Biol. 23, 1833\u20131838 (2003).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2673_CR340","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1210\/er.2005-0014","volume":"27","author":"LR Potter","year":"2006","unstructured":"Potter, L. R., Abbey-Hosch, S. & Dickey, D. M. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev. 27, 47\u201372 (2006).","journal-title":"Endocr. Rev."},{"key":"2673_CR341","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/ng.3660","volume":"48","author":"C Liu","year":"2016","unstructured":"Liu, C. et al. Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. Nat. Genet. 48, 1162\u20131170 (2016).","journal-title":"Nat. Genet."},{"key":"2673_CR342","doi-asserted-by":"publisher","first-page":"e13699","DOI":"10.1111\/acel.13699","volume":"21","author":"C Long","year":"2022","unstructured":"Long, C. et al. Chronological attenuation of NPRA\/PKG\/AMPK signaling promotes vascular aging and elevates blood pressure. Aging Cell 21, e13699 (2022).","journal-title":"Aging Cell"},{"key":"2673_CR343","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1111\/joim.13352","volume":"290","author":"KJ Olczak","year":"2021","unstructured":"Olczak, K. J. et al. Hypertension genetics past, present and future applications. J. Intern. Med. 290, 1130\u20131152 (2021).","journal-title":"J. Intern. Med."},{"key":"2673_CR344","doi-asserted-by":"publisher","first-page":"A13840","DOI":"10.1161\/circ.148.suppl_1.13840","volume":"148","author":"AP Kithcart","year":"2023","unstructured":"Kithcart, A. P. et al. Abstract 13840: safety outcomes from a first-in-human study of a novel investigational monoclonal antibody, REGN5381, an agonist to the natriuretic peptide receptor 1. Circulation 148, A13840 (2023).","journal-title":"Circulation"},{"key":"2673_CR345","doi-asserted-by":"publisher","first-page":"107863","DOI":"10.1016\/j.pharmthera.2021.107863","volume":"227","author":"K Kuwahara","year":"2021","unstructured":"Kuwahara, K. The natriuretic peptide system in heart failure: diagnostic and therapeutic implications. Pharmacol. Ther. 227, 107863 (2021).","journal-title":"Pharmacol. Ther."},{"key":"2673_CR346","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-024-07903-1","volume":"633","author":"ME Dunn","year":"2024","unstructured":"Dunn, M. E. et al. Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone. Nature 633, 654\u2013661 (2024).","journal-title":"Nature"},{"key":"2673_CR347","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJM199908193410806","volume":"341","author":"RW Schrier","year":"1999","unstructured":"Schrier, R. W. & Abraham, W. T. Hormones and hemodynamics in heart failure. N. Engl. J. Med. 341, 577\u2013585 (1999).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR348","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10741-008-9127-5","volume":"14","author":"M Metra","year":"2009","unstructured":"Metra, M. et al. Vasodilators in the treatment of acute heart failure: what we know, what we don\u2019t. Heart Fail. Rev. 14, 299\u2013307 (2009).","journal-title":"Heart Fail. Rev."},{"key":"2673_CR349","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/ejhf.872","volume":"19","author":"VP Harjola","year":"2017","unstructured":"Harjola, V. P. et al. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. J. Heart Fail. 19, 821\u2013836 (2017).","journal-title":"Eur. J. Heart Fail."},{"key":"2673_CR350","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1126\/science.1065654","volume":"295","author":"SY Hsu","year":"2002","unstructured":"Hsu, S. Y. et al. Activation of orphan receptors by the hormone relaxin. Science 295, 671\u2013674 (2002).","journal-title":"Science"},{"key":"2673_CR351","doi-asserted-by":"publisher","first-page":"8217","DOI":"10.1096\/fj.201902506R","volume":"34","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. The anti-fibrotic actions of relaxin are mediated through AT(2) R-associated protein phosphatases via RXFP1-AT(2) R functional crosstalk in human cardiac myofibroblasts. FASEB J. 34, 8217\u20138233 (2020).","journal-title":"FASEB J."},{"key":"2673_CR352","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/bph.13523","volume":"174","author":"M Sarwar","year":"2017","unstructured":"Sarwar, M., Du, X. J., Dschietzig, T. B. & Summers, R. J. The actions of relaxin on the human cardiovascular system. Br. J. Pharmacol. 174, 933\u2013949 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"2673_CR353","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1016\/j.ymthe.2021.04.010","volume":"29","author":"N Sasipong","year":"2021","unstructured":"Sasipong, N. et al. Ligand-activated RXFP1 gene therapy ameliorates pressure overload-induced cardiac dysfunction. Mol. Ther. 29, 2499\u20132513 (2021).","journal-title":"Mol. Ther."},{"key":"2673_CR354","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1111\/j.1476-5381.2011.01470.x","volume":"165","author":"ML Halls","year":"2012","unstructured":"Halls, M. L. Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation. Br. J. Pharmacol. 165, 1644\u20131658 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"2673_CR355","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/eurheartj\/eht459","volume":"35","author":"P Ponikowski","year":"2014","unstructured":"Ponikowski, P. et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur. Heart J. 35, 431\u2013441 (2014).","journal-title":"Eur. Heart J."},{"key":"2673_CR356","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","volume":"381","author":"JR Teerlink","year":"2013","unstructured":"Teerlink, J. R. et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381, 29\u201339 (2013).","journal-title":"Lancet"},{"key":"2673_CR357","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1056\/NEJMoa1801291","volume":"381","author":"M Metra","year":"2019","unstructured":"Metra, M. et al. Effects of serelaxin in patients with acute heart failure. N. Engl. J. Med. 381, 716\u2013726 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR358","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/ndt\/gfae112","volume":"40","author":"LS Tham","year":"2024","unstructured":"Tham, L. S. et al. Volenrelaxin (LY3540378) increases renal plasma flow: a randomized phase 1 trial. Nephrol. Dial. Transplant. 40, 109\u2013122 (2024).","journal-title":"Nephrol. Dial. Transplant."},{"key":"2673_CR359","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034067","volume":"13","author":"K Connolly","year":"2024","unstructured":"Connolly, K. et al. Novel relaxin receptor RXFP1 agonist AZD3427 in the treatment of heart failure: a phase 1a\/b, first-in-human, randomized, single-blind, placebo-controlled study. J. Am. Heart Assoc. 13, e034067 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"2673_CR360","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41581-022-00654-0","volume":"19","author":"JA O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell, J. A., Zheng, T., Meric, G. & Marques, F. Z. The gut microbiome and hypertension. Nat. Rev. Nephrol. 19, 153\u2013167 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"2673_CR361","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1161\/CIRCRESAHA.121.318082","volume":"128","author":"DG Harrison","year":"2021","unstructured":"Harrison, D. G., Coffman, T. M. & Wilcox, C. S. Pathophysiology of hypertension: the mosaic theory and beyond. Circ. Res. 128, 847\u2013863 (2021).","journal-title":"Circ. Res."},{"key":"2673_CR362","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1126\/science.1223813","volume":"336","author":"JK Nicholson","year":"2012","unstructured":"Nicholson, J. K. et al. Host-gut microbiota metabolic interactions. Science 336, 1262\u20131267 (2012).","journal-title":"Science"},{"key":"2673_CR363","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03296-9","volume":"20","author":"P Gebrayel","year":"2022","unstructured":"Gebrayel, P. et al. Microbiota medicine: towards clinical revolution. J. Transl. Med. 20, 111 (2022).","journal-title":"J. Transl. Med."},{"key":"2673_CR364","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00424-019-02322-y","volume":"471","author":"M Onyszkiewicz","year":"2019","unstructured":"Onyszkiewicz, M. et al. Butyric acid, a gut bacteria metabolite, lowers arterial blood pressure via colon-vagus nerve signaling and GPR41\/43 receptors. Pflug. Arch. 471, 1441\u20131453 (2019).","journal-title":"Pflug. Arch."},{"key":"2673_CR365","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1161\/CIRCULATIONAHA.116.024545","volume":"135","author":"FZ Marques","year":"2017","unstructured":"Marques, F. Z. et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation 135, 964\u2013977 (2017).","journal-title":"Circulation"},{"key":"2673_CR366","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1161\/CIRCULATIONAHA.119.043081","volume":"141","author":"DM Kaye","year":"2020","unstructured":"Kaye, D. M. et al. Deficiency of prebiotic fiber and insufficient signaling through gut metabolite-sensing receptors leads to cardiovascular disease. Circulation 141, 1393\u20131403 (2020).","journal-title":"Circulation"},{"key":"2673_CR367","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1161\/CIRCULATIONAHA.118.036652","volume":"139","author":"H Bartolomaeus","year":"2019","unstructured":"Bartolomaeus, H. et al. Short-chain fatty acid propionate protects from hypertensive cardiovascular damage. Circulation 139, 1407\u20131421 (2019).","journal-title":"Circulation"},{"key":"2673_CR368","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101706","volume":"81","author":"T Hu","year":"2022","unstructured":"Hu, T. et al. Short-chain fatty acid metabolism and multiple effects on cardiovascular diseases. Ageing Res. Rev. 81, 101706 (2022).","journal-title":"Ageing Res. Rev."},{"key":"2673_CR369","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s44161-022-00197-4","volume":"2","author":"HA JAMA","year":"2023","unstructured":"JAMA, H. A. et al. Prebiotic intervention with HAMSAB in untreated essential hypertensive patients assessed in a phase II randomized trial. Nat. Cardiovasc.Res. 2, 35\u201343 (2023).","journal-title":"Nat. Cardiovasc.Res."},{"key":"2673_CR370","unstructured":"Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 397, 1625\u20131636, (2021)."},{"key":"2673_CR371","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41569-023-00840-y","volume":"20","author":"K Huynh","year":"2023","unstructured":"Huynh, K. Microbial metabolites reduce SBP in patients with resistant hypertension. Nat. Rev. Cardiol. 20, 140 (2023).","journal-title":"Nat. Rev. Cardiol."},{"key":"2673_CR372","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06086-2","volume":"23","author":"L Fan","year":"2022","unstructured":"Fan, L. et al. Effect of fecal microbiota transplantation on primary hypertension and the underlying mechanism of gut microbiome restoration: protocol of a randomized, blinded, placebo-controlled study. Trials 23, 178 (2022).","journal-title":"Trials"},{"key":"2673_CR373","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.679624","volume":"11","author":"HJ Zhong","year":"2021","unstructured":"Zhong, H. J. et al. Washed Microbiota Transplantation Lowers Blood Pressure in Patients With Hypertension. Front. Cell. Infect. Microbiol. 11, 679624 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"2673_CR374","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1039\/D2FO00038E","volume":"13","author":"Q Zhu","year":"2022","unstructured":"Zhu, Q. et al. Moderation of gut microbiota and bile acid metabolism by chlorogenic acid improves high-fructose-induced salt-sensitive hypertension in mice. Food Funct. 13, 6987\u20136999 (2022).","journal-title":"Food Funct."},{"key":"2673_CR375","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/CIRCRESAHA.120.318155","volume":"128","author":"H Shi","year":"2021","unstructured":"Shi, H. et al. Restructuring the gut microbiota by intermittent fasting lowers blood pressure. Circ. Res. 128, 1240\u20131254 (2021).","journal-title":"Circ. Res."},{"key":"2673_CR376","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41586-020-2193-0","volume":"581","author":"C Campbell","year":"2020","unstructured":"Campbell, C. et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 581, 475\u2013479 (2020).","journal-title":"Nature"},{"key":"2673_CR377","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2024.127824","volume":"287","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Berberine ameliorates vascular dysfunction by downregulating TMAO-endoplasmic reticulum stress pathway via gut microbiota in hypertension. Microbiol. Res. 287, 127824 (2024).","journal-title":"Microbiol. Res."},{"key":"2673_CR378","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03687-y","volume":"20","author":"KM Maksymiuk","year":"2022","unstructured":"Maksymiuk, K. M. et al. Trimethylamine, a gut bacteria metabolite and air pollutant, increases blood pressure and markers of kidney damage including proteinuria and KIM-1 in rats. J. Transl. Med. 20, 470 (2022).","journal-title":"J. Transl. Med."},{"key":"2673_CR379","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102115","volume":"46","author":"S Jiang","year":"2021","unstructured":"Jiang, S. et al. Gut microbiota dependent trimethylamine N-oxide aggravates angiotensin II-induced hypertension. Redox Biol. 46, 102115 (2021).","journal-title":"Redox Biol."},{"key":"2673_CR380","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/HYPERTENSIONAHA.120.16895","volume":"78","author":"VE Brunt","year":"2021","unstructured":"Brunt, V. E. et al. Gut microbiome-derived metabolite trimethylamine N-oxide induces aortic stiffening and increases systolic blood pressure with aging in mice and humans. Hypertension 78, 499\u2013511 (2021).","journal-title":"Hypertension"},{"key":"2673_CR381","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.123.067957","volume":"150","author":"TR Damase","year":"2024","unstructured":"Damase, T. R. et al. Established and emerging nucleic acid therapies for familial hypercholesterolemia. Circulation 150, 724\u2013735 (2024).","journal-title":"Circulation"},{"key":"2673_CR382","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40265-024-01995-9","volume":"84","author":"WAM Schonck","year":"2024","unstructured":"Schonck, W. A. M., Stroes, E. S. G., Hovingh, G. K. & Reeskamp, L. F. Long-term efficacy and tolerability of PCSK9 targeted therapy: a review of the literature. Drugs 84, 165\u2013178 (2024).","journal-title":"Drugs"},{"key":"2673_CR383","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference, B. A. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 38, 2459\u20132472 (2017).","journal-title":"Eur. Heart J."},{"key":"2673_CR384","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n, J. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 41, 2313\u20132330 (2020).","journal-title":"Eur. Heart J."},{"key":"2673_CR385","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","volume":"9","author":"X Bao","year":"2024","unstructured":"Bao, X. et al. Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct. Target. Ther. 9, 13 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2673_CR386","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz, G. G. et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. 379, 2097\u20132107 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR387","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR388","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue, M. L. et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation 146, 1109\u20131119 (2022).","journal-title":"Circulation"},{"key":"2673_CR389","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029216","volume":"12","author":"SG Goodman","year":"2023","unstructured":"Goodman, S. G. et al. Long-term efficacy, safety, and tolerability of alirocumab in 8242 patients eligible for 3 to 5\u2009years of placebo-controlled observation in the ODYSSEY OUTCOMES Trial. J. Am. Heart Assoc. 12, e029216 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"2673_CR390","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/MOL.0000000000000919","volume":"35","author":"JL Katzmann","year":"2024","unstructured":"Katzmann, J. L. & Laufs, U. PCSK9-directed therapies: an update. Curr. Opin. Lipidol. 35, 117\u2013125 (2024).","journal-title":"Curr. Opin. Lipidol."},{"key":"2673_CR391","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1093\/eurheartj\/ehad566","volume":"44","author":"U Laufs","year":"2023","unstructured":"Laufs, U., Bl\u00fcher, M. & Isermann, B. Third generation PCSK9-inhibitors. Eur. Heart J. 44, 4281\u20134283 (2023).","journal-title":"Eur. Heart J."},{"key":"2673_CR392","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00228-021-03149-2","volume":"77","author":"M Zeitlinger","year":"2021","unstructured":"Zeitlinger, M. et al. A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. Eur. J. Clin. Pharmacol. 77, 1473\u20131484 (2021).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2673_CR393","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/vaccines9070749","volume":"9","author":"AA Momtazi-Borojeni","year":"2021","unstructured":"Momtazi-Borojeni, A. A. et al. Pre-clinical evaluation of the nanoliposomal antiPCSK9 vaccine in healthy non-human primates. Vaccines 9, 749 (2021).","journal-title":"Vaccines"},{"key":"2673_CR394","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00743-6","volume":"8","author":"A Fowler","year":"2023","unstructured":"Fowler, A. et al. A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates. NPJ Vaccines 8, 142 (2023).","journal-title":"NPJ Vaccines"},{"key":"2673_CR395","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","volume":"147","author":"RG Lee","year":"2023","unstructured":"Lee, R. G. et al. Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation 147, 242\u2013253 (2023).","journal-title":"Circulation"},{"key":"2673_CR396","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/ehjcvp\/pvad103","volume":"10","author":"T Horie","year":"2024","unstructured":"Horie, T. & Ono, K. VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients. Eur. Heart J. Cardiovasc. Pharmacother. 10, 89\u201390 (2024).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"2673_CR397","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1038\/s41591-023-02699-5","volume":"29","author":"C Arnold","year":"2023","unstructured":"Arnold, C. & Webster, P. 11 clinical trials that will shape medicine in 2024. Nat. Med. 29, 2964\u20132968 (2023).","journal-title":"Nat. Med."},{"key":"2673_CR398","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/13543784.2024.2369747","volume":"33","author":"AJ Hooper","year":"2024","unstructured":"Hooper, A. J., Tang, X. L. & Burnett, J. R. VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol. Expert Opin. Investig. Drugs 33, 753\u2013756 (2024).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2673_CR399","doi-asserted-by":"publisher","first-page":"ehac544.3087","DOI":"10.1093\/eurheartj\/ehac544.3087","volume":"43","author":"A Khera","year":"2022","unstructured":"Khera, A. et al. An in vivo CRISPR base editing therapy to inactivate the ANGPTL3 gene: nomination of a development candidate for VERVE-201. Eur. Heart J. 43, ehac544.3087 (2022).","journal-title":"Eur. Heart J."},{"key":"2673_CR400","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","volume":"137","author":"AC Chadwick","year":"2018","unstructured":"Chadwick, A. C., Evitt, N. H., Lv, W. & Musunuru, K. Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3. Circulation 137, 975\u2013977 (2018).","journal-title":"Circulation"},{"key":"2673_CR401","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","volume":"141","author":"H Zhao","year":"2020","unstructured":"Zhao, H. et al. In vivo AAV-CRISPR\/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia. Circulation 141, 67\u201379 (2020).","journal-title":"Circulation"},{"key":"2673_CR402","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1161\/CIRCRESAHA.122.321938","volume":"132","author":"BL Clifford","year":"2023","unstructured":"Clifford, B. L. et al. RNF130 regulates LDLR availability and plasma LDL cholesterol levels. Circ. Res. 132, 849\u2013863 (2023).","journal-title":"Circ. Res."},{"key":"2673_CR403","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jacc.2015.02.017","volume":"65","author":"S Bangalore","year":"2015","unstructured":"Bangalore, S. et al. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial. J. Am. Coll. Cardiol. 65, 1539\u20131548 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR404","doi-asserted-by":"publisher","first-page":"33742","DOI":"10.1074\/jbc.M203215200","volume":"277","author":"T Shimizugawa","year":"2002","unstructured":"Shimizugawa, T. et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J. Biol. Chem. 277, 33742\u201333748 (2002).","journal-title":"J. Biol. Chem."},{"key":"2673_CR405","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey, F. E. et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N. Engl. J. Med. 377, 211\u2013221 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR406","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","volume":"149","author":"A Wiegman","year":"2024","unstructured":"Wiegman, A. et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. Circulation 149, 343\u2013353 (2024).","journal-title":"Circulation"},{"key":"2673_CR407","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","volume":"11","author":"KK Ray","year":"2023","unstructured":"Ray, K. K. et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 11, 109\u2013119 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2673_CR408","doi-asserted-by":"publisher","first-page":"A17120","DOI":"10.1161\/circ.148.suppl_1.17120","volume":"148","author":"GF Watts","year":"2023","unstructured":"Watts, G. F. et al. Abstract 17120: ARO-ANG3, an investigational RNAi therapeutic, silences the expression of ANGPTL3 and decreases atherogenic lipoproteins in patients with mixed dyslipidemia: ARCHES-2 study results. Circulation 148, A17120 (2023).","journal-title":"Circulation"},{"key":"2673_CR409","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1161\/ATVBAHA.118.311476","volume":"39","author":"G Reyes-Soffer","year":"2019","unstructured":"Reyes-Soffer, G. et al. Effects of APOC3 heterozygous deficiency on plasma lipid and lipoprotein metabolism. Arterioscler. Thromb. Vasc. Biol. 39, 63\u201372 (2019).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2673_CR410","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"371","author":"D Gaudet","year":"2014","unstructured":"Gaudet, D. et al. Targeting APOC3 in the familial chylomicronemia syndrome. N. Engl. J. Med. 371, 2200\u20132206 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR411","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","volume":"29","author":"RS Rosenson","year":"2023","unstructured":"Rosenson, R. S. et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat. Med. 29, 729\u2013737 (2023).","journal-title":"Nat. Med."},{"key":"2673_CR412","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1161\/ATVBAHA.117.310473","volume":"38","author":"AB Wulff","year":"2018","unstructured":"Wulff, A. B., Nordestgaard, B. G. & Tybj\u00e6rg-Hansen, A. APOC3 loss-of-function mutations, remnant cholesterol, low-density lipoprotein cholesterol, and cardiovascular risk: mediation- and meta-analyses of 137\u2009895 individuals. Arterioscler. Thromb. Vasc. Biol. 38, 660\u2013668 (2018).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2673_CR413","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"J Crosby","year":"2014","unstructured":"Crosby, J. et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 371, 22\u201331 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR414","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum, J. L. et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N. Engl. J. Med. 381, 531\u2013542 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR415","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMc1912350","volume":"381","author":"SA Khetarpal","year":"2019","unstructured":"Khetarpal, S. A., Wang, M. & Khera, A. V. Volanesorsen, familial chylomicronemia syndrome, and thrombocytopenia. N. Engl. J. Med. 381, 2582\u20132584 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR416","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","volume":"43","author":"JC Tardif","year":"2022","unstructured":"Tardif, J. C. et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur. Heart J. 43, 1401\u20131412 (2022).","journal-title":"Eur. Heart J."},{"key":"2673_CR417","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","volume":"40","author":"VJ Alexander","year":"2019","unstructured":"Alexander, V. J. et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur. Heart J. 40, 2785\u20132796 (2019).","journal-title":"Eur. Heart J."},{"key":"2673_CR418","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark, B. A. et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N. Engl. J. Med. 390, 1770\u20131780 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR419","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet, D. et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. 9, 620\u2013630 (2024).","journal-title":"JAMA Cardiol."},{"key":"2673_CR420","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2022.10.004","volume":"363","author":"R Rikhi","year":"2022","unstructured":"Rikhi, R. et al. Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 363, 102\u2013108 (2022).","journal-title":"Atherosclerosis"},{"key":"2673_CR421","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","volume":"3","author":"S Burgess","year":"2018","unstructured":"Burgess, S. et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 3, 619\u2013627 (2018).","journal-title":"JAMA Cardiol."},{"key":"2673_CR422","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014711","volume":"9","author":"M Afshar","year":"2020","unstructured":"Afshar, M. et al. Risks of incident cardiovascular disease associated with concomitant elevations in lipoprotein(a) and low-density lipoprotein cholesterol-the Framingham Heart Study. J. Am. Heart Assoc. 9, e014711 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"2673_CR423","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.103843","volume":"35","author":"A Cesaro","year":"2025","unstructured":"Cesaro, A. et al. Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): impact of lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease. Nutr. Metab. Cardiovasc. Dis. 35, 103843 (2025).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"2673_CR424","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas, S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J. Am. Coll. Cardiol. 69, 692\u2013711 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR425","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/sj.ejhg.5201512","volume":"14","author":"K Schmidt","year":"2006","unstructured":"Schmidt, K., Kraft, H. G., Parson, W. & Utermann, G. Genetics of the Lp(a)\/apo(a) system in an autochthonous Black African population from the Gabon. Eur. J. Hum. Genet. 14, 190\u2013201 (2006).","journal-title":"Eur. J. Hum. Genet."},{"key":"2673_CR426","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1172\/JCI115855","volume":"90","author":"E Boerwinkle","year":"1992","unstructured":"Boerwinkle, E. et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 90, 52\u201360 (1992).","journal-title":"J. Clin. Invest."},{"key":"2673_CR427","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","volume":"273","author":"F Kronenberg","year":"2013","unstructured":"Kronenberg, F. & Utermann, G. Lipoprotein(a): resurrected by genetics. J. Intern. Med. 273, 6\u201330 (2013).","journal-title":"J. Intern. Med."},{"key":"2673_CR428","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","volume":"40","author":"CM Madsen","year":"2020","unstructured":"Madsen, C. M. et al. Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study. Arterioscler. Thromb. Vasc. Biol. 40, 255\u2013266 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2673_CR429","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eprac.2022.12.011","volume":"29","author":"T Tsushima","year":"2023","unstructured":"Tsushima, T., Tsushima, Y., Sullivan, C. & Hatipoglu, B. Lipoprotein(a) and atherosclerotic cardiovascular disease, the impact of available lipid-lowering medications on lipoprotein(a): an update on new therapies. Endocr. Pract. 29, 491\u2013497 (2023).","journal-title":"Endocr. Pract."},{"key":"2673_CR430","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney, N. J. et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388, 2239\u20132253 (2016).","journal-title":"Lancet"},{"key":"2673_CR431","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","volume":"386","author":"S Tsimikas","year":"2015","unstructured":"Tsimikas, S. et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386, 1472\u20131483 (2015).","journal-title":"Lancet"},{"key":"2673_CR432","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas, S. et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N. Engl. J. Med. 382, 244\u2013255 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR433","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano, A. L. et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur. Heart J. 37, 2999\u20133058 (2016).","journal-title":"Eur. Heart J."},{"key":"2673_CR434","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy, S. M. et al. AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 73, e285\u2013e350 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR435","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12944-022-01649-3","volume":"21","author":"DJ Blom","year":"2022","unstructured":"Blom, D. J. et al. RNA-based therapy in the management of lipid disorders: a review. Lipids Health Dis. 21, 41 (2022).","journal-title":"Lipids Health Dis."},{"key":"2673_CR436","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue, M. L. et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N. Engl. J. Med. 387, 1855\u20131864 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR437","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2024.4504","volume":"331","author":"SE Nissen","year":"2024","unstructured":"Nissen, S. E. et al. Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial. JAMA 331, 1534\u20131543 (2024).","journal-title":"JAMA"},{"key":"2673_CR438","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","volume":"330","author":"SE Nissen","year":"2023","unstructured":"Nissen, S. E. et al. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial. JAMA 330, 2075\u20132083 (2023).","journal-title":"JAMA"},{"key":"2673_CR439","doi-asserted-by":"crossref","unstructured":"Rye, K. A. et al. The metabolism and anti-atherogenic properties of HDL. J. Lipid Res 50 (Suppl)., S195\u2013S200 (2009).","DOI":"10.1194\/jlr.R800034-JLR200"},{"key":"2673_CR440","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1161\/CIRCULATIONAHA.120.044221","volume":"143","author":"A Rohatgi","year":"2021","unstructured":"Rohatgi, A. et al. HDL in the 21st century: a multifunctional roadmap for future HDL research. Circulation 143, 2293\u20132309 (2021).","journal-title":"Circulation"},{"key":"2673_CR441","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","volume":"370","author":"S Lewington","year":"2007","unstructured":"Lewington, S. et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370, 1829\u20131839 (2007).","journal-title":"Lancet"},{"key":"2673_CR442","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"E Di Angelantonio","year":"2009","unstructured":"Di Angelantonio, E. et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993\u20132000 (2009).","journal-title":"JAMA"},{"key":"2673_CR443","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1056\/NEJMoa2400969","volume":"390","author":"CM Gibson","year":"2024","unstructured":"Gibson, C. M. et al. Apolipoprotein A1 infusions and cardiovascular outcomes after acute myocardial infarction. N. Engl. J. Med. 390, 1560\u20131571 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2673_CR444","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1161\/CIRCULATIONAHA.122.059325","volume":"146","author":"MP Bonaca","year":"2022","unstructured":"Bonaca, M. P. et al. Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: results of REAL-TIMI 63B. Circulation. 146, 907\u2013916 (2022).","journal-title":"Circulation."},{"key":"2673_CR445","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1161\/ATVBAHA.113.301981","volume":"33","author":"S Diditchenko","year":"2013","unstructured":"Diditchenko, S. et al. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 33, 2202\u20132211 (2013).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2673_CR446","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s11883-023-01176-1","volume":"25","author":"F Begue","year":"2023","unstructured":"Begue, F., Apalama, M. L., Lambert, G. & Meilhac, O. HDL as a treatment target: should we abandon this idea? Curr. Atheroscler. Rep. 25, 1093\u20131099 (2023).","journal-title":"Curr. Atheroscler. Rep."},{"key":"2673_CR447","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.drudis.2021.03.016","volume":"26","author":"S Banerjee","year":"2021","unstructured":"Banerjee, S. & De, A. Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases: an update. Drug Discov. Today 26, 1759\u20131764 (2021).","journal-title":"Drug Discov. Today"},{"key":"2673_CR448","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","volume":"122","author":"AR Tall","year":"2018","unstructured":"Tall, A. R. & Rader, D. J. Trials and tribulations of CETP inhibitors. Circ. Res. 122, 106\u2013112 (2018).","journal-title":"Circ. Res."},{"key":"2673_CR449","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25703-3","volume":"12","author":"AF Schmidt","year":"2021","unstructured":"Schmidt, A. F. et al. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nat. Commun. 12, 5640 (2021).","journal-title":"Nat. Commun."},{"key":"2673_CR450","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls, S. J. et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat. Med. 28, 1672\u20131678 (2022).","journal-title":"Nat. Med."},{"key":"2673_CR451","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","volume":"17","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne, C. M. et al. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial. J. Clin. Lipidol. 17, 491\u2013503 (2023).","journal-title":"J. Clin. Lipidol."},{"key":"2673_CR452","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.arcmed.2019.01.007","volume":"49","author":"R Guti\u00e9rrez-Vidal","year":"2018","unstructured":"Guti\u00e9rrez-Vidal, R. et al. Therapeutic intranasal vaccine HB-ATV-8 prevents atherogenesis and non-alcoholic fatty liver disease in a pig model of atherosclerosis. Arch. Med. Res. 49, 456\u2013470 (2018).","journal-title":"Arch. Med. Res."},{"key":"2673_CR453","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/10837450.2019.1706181","volume":"25","author":"T Aghebati","year":"2020","unstructured":"Aghebati, T. et al. Development of an effective liposomal cholesterol ester transfer protein (CETP) vaccine for protecting against atherosclerosis in rabbit model. Pharm. Dev. Technol. 25, 432\u2013439 (2020).","journal-title":"Pharm. Dev. Technol."},{"key":"2673_CR454","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41569-020-00499-9","volume":"18","author":"S Sahoo","year":"2021","unstructured":"Sahoo, S., Kariya, T. & Ishikawa, K. Targeted delivery of therapeutic agents to the heart. Nat. Rev. Cardiol. 18, 389\u2013399 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"2673_CR455","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.molmed.2022.10.002","volume":"29","author":"A Vila\u00e7a","year":"2023","unstructured":"Vila\u00e7a, A., de Windt, L. J., Fernandes, H. & Ferreira, L. Strategies and challenges for non-viral delivery of non-coding RNAs to the heart. Trends Mol. Med. 29, 70\u201391 (2023).","journal-title":"Trends Mol. Med."},{"key":"2673_CR456","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41573-024-01051-x","volume":"23","author":"PJ Carter","year":"2024","unstructured":"Carter, P. J. & Quarmby, V. Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics. Nat. Rev. Drug Discov. 23, 898\u2013913 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2673_CR457","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","volume":"185","author":"A Raguram","year":"2022","unstructured":"Raguram, A., Banskota, S. & Liu, D. R. Therapeutic in vivo delivery of gene editing agents. Cell 185, 2806\u20132827 (2022).","journal-title":"Cell"},{"key":"2673_CR458","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-024-01633-7","volume":"17","author":"W Zhang","year":"2024","unstructured":"Zhang, W. & Huang, X. In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy. J. Hematol. Oncol. 17, 110 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2673_CR459","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","volume":"23","author":"PR Cullis","year":"2024","unstructured":"Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug Discov. 23, 709\u2013722 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2673_CR460","doi-asserted-by":"publisher","first-page":"115461","DOI":"10.1016\/j.addr.2024.115461","volume":"215","author":"J Bader","year":"2024","unstructured":"Bader, J., Brigger, F. & Leroux, J. C. Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids. Adv. Drug Deliv. Rev. 215, 115461 (2024).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2673_CR461","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1038\/s41596-021-00554-w","volume":"16","author":"L Gieselmann","year":"2021","unstructured":"Gieselmann, L. et al. Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. Nat. Protoc. 16, 3639\u20133671 (2021).","journal-title":"Nat. Protoc."},{"key":"2673_CR462","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s43018-023-00516-z","volume":"4","author":"S Zinn","year":"2023","unstructured":"Zinn, S. et al. Advances in antibody-based therapy in oncology. Nat. Cancer 4, 165\u2013180 (2023).","journal-title":"Nat. Cancer"},{"key":"2673_CR463","doi-asserted-by":"publisher","first-page":"10365","DOI":"10.3390\/ijms251910365","volume":"25","author":"L Giorgioni","year":"2024","unstructured":"Giorgioni, L. et al. Revolutionizing CAR T-cell therapies: innovations in genetic engineering and manufacturing to enhance efficacy and accessibility. Int. J. Mol. Sci. 25, 10365 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2673_CR464","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.jacc.2024.08.069","volume":"84","author":"JW Cunningham","year":"2024","unstructured":"Cunningham, J. W. et al. Artificial intelligence in cardiovascular clinical trials. J. Am. Coll. Cardiol. 84, 2051\u20132062 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2673_CR465","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1093\/eurheartj\/ehae465","volume":"45","author":"TF L\u00fcscher","year":"2024","unstructured":"L\u00fcscher, T. F. et al. Artificial intelligence in cardiovascular medicine: clinical applications. Eur. Heart J. 45, 4291\u20134304 (2024).","journal-title":"Eur. Heart J."},{"key":"2673_CR466","doi-asserted-by":"publisher","first-page":"e749","DOI":"10.1016\/S2589-7500(24)00155-9","volume":"6","author":"A Mihan","year":"2024","unstructured":"Mihan, A., Pandey, A. & Van Spall, H. G. Mitigating the risk of artificial intelligence bias in cardiovascular care. Lancet Digit. Health 6, e749\u2013e754 (2024).","journal-title":"Lancet Digit. Health"},{"key":"2673_CR467","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ejhf.3139","volume":"26","author":"J Bauersachs","year":"2024","unstructured":"Bauersachs, J. et al. Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial. Eur. J. Heart Fail. 26, 674\u2013682 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"2673_CR468","volume":"2023","author":"S Kotit","year":"2023","unstructured":"Kotit, S. Lessons from the first-in-human in vivo CRISPR\/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy. Glob. Cardiol. Sci. Pract. 2023, e202304 (2023).","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"2673_CR469","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2023.102937","volume":"55","author":"S Calixto-Tlacomulco","year":"2024","unstructured":"Calixto-Tlacomulco, S. et al. CETP-derived peptide Seq-1, the key component of HB-ATV-8 vaccine prevents stress responses, and promotes downregulation of pro-fibrotic genes in hepatocytes and stellate cells. Arch. Med. Res. 55, 102937 (2024).","journal-title":"Arch. Med. Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02673-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02673-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02673-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T23:03:05Z","timestamp":1782687785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02673-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":469,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2673"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02673-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"252"}}